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Fluoroquinolones (FQs) are broad-spectrum charged antimicrobials exhibiting excellent 
tissue/fluid permeation. Thus, FQ disposition depends essentially on active transport and 
facilitative diffusion. Although most early transporter studies investigating renal elimination of 
FQs have focused on apical efflux of FQs from renal proximal tubule cell (RPTC) into urine, 
their basolateral uptake mechanism(s) from blood into RPTC (i.e., first step to tubular secretion) 
has not yet been explored in detail. Renally expressed SLC22 members: organic anion (OATs) 
xiv 
 
 
 
and cation (OCTs) transporters are known to transport such small organic ionic substrates 
(molecular weight ~400 Da). Hence it is of interest to explore the role of these basolateral 
transporters in renal elimination of FQs, and to further quantitatively assess their impact in 
clinically observed FQ drug-drug interactions (DDI).  
An initial systematic review of clinical literature for FQs (n=18) demonstrated substantial 
differences among their renal clearance (CLren~46-fold) and unbound renal clearance (CLren
u
~20-
fold), and suggested that tubular secretion and reabsorption could be major determinants of FQ 
half-life, efficacy, and DDIs. FQs (n=13) identified from the above review were investigated by 
in-vitro transport studies using stably transfected cell lines, for potential interactions with organic 
cation [human (h) OCT1, hOCT2 and hOCT3] and anion [mouse (m) and hOAT3, hOAT1; and 
hOAT4] transporters. Further, kinetic inhibition studies were conducted to determine inhibition 
potency (Ki/IC50 values) for those FQs exhibiting significant OCT/OAT inhibition in preliminary 
interaction experiments. 
 Gatifloxacin, moxifloxacin, prulifloxacin, and sparfloxacin were determined to be 
competitive inhibitors of hOCT1 with Ki = 250±18, 161±19, 136±33, and 94±8 µM, 
respectively. Moxifloxacin competitively inhibited hOCT3-mediated uptake, Ki = 1,598±146 
µM. Enoxacin, fleroxacin, levofloxacin, lomefloxacin, moxifloxacin, prulifloxacin, and 
sparfloxacin exhibited competitive inhibition for mOat3 with Ki = 396±15, 817±31, 515±22, 
539±27, 1356±114, 299±35, 205±12 µM, respectively. Fleroxacin and pefloxacin were found to 
inhibit hOAT1 with IC50 = 2228±84 and 1819±144 respectively. Despite expression in 
enterocytes, hepatocytes, and RPTC, hOCT3 does not appear to contribute significantly to FQ 
disposition. However, due to hepatic and potential RPTC expression, hOCT1 could play an 
xv 
 
 
 
important role in elimination of these antimicrobials. Among renally expressed OATs in humans, 
hOAT1 and hOAT3 are likely to be involved in FQ elimination. 
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CHAPTER 1 
 
ROLE OF RENAL SECRETORY AND REABSORPTIVE DRUG TRANSPORTERS IN 
SYSTEMIC DISPOSITION OF FLUOROQUINOLONES 
 
Drawn from manuscript published in Expert Opin Drug Metab Toxicol. May 2012; 8(5): 553-69 
 
 
 
 
 1. A. INTRODUCTION 
Recently, ciprofloxacin gained notoriety when it was used for the prophylaxis and treatment 
of Anthrax infection during the 2001 bioterrorist attacks which killed several people in the 
United States. However, as a class, quinolones have been employed in the treatment of bacterial 
infections for nearly 50 years. The first quinolone, nalidixic acid, was identified as an extremely 
effective agent in the treatment of urinary tract infections, but it suffered from poor oral 
absorption, short half-life, and its efficacy was limited to a narrow range of anaerobic gram-
negative organisms (9, 141). Further intensive structure-activity relationship studies led to the 
development of successive generations of FQs which mainly improved their in vitro 
antimicrobial activity, i.e., being effective against a broader range of gram-negative microbes, 
some gram-positive organisms, and exhibiting higher potencies. 
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One of the earliest quinolone modifications was substitution of a hydrogen by a fluorine atom 
at position 6 of the 4-quinolone ring (Figure 1.1), resulting in these agents being referred to as 
fluoroquinolones (FQs), with flumequine being the first FQ (9, 141). 
Second-generation FQs (e.g., ciprofloxacin, enoxacin, norfloxacin, ofloxacin) demonstrate 
increased activity against gram-negative bacteria, as well as Staphylococcus species, and 
improved tissue penetration, broadening their spectrum of use to include certain respiratory tract 
and soft-tissue infections. Third-generation FQs (e.g., grepafloxacin, levofloxacin, sparfloxacin) 
can be taken once daily – as a result of their prolonged half-life - and are also effective against 
some gram-positive organisms and atypical pathogens including species of Chlamydia, 
Haemophilus, Legionella, and Mycoplasma (9, 98, 141). Coupled with excellent oral 
bioavailability, their therapeutic indications were expanded to include treatment of conditions 
such as community-acquired pneumonia, acute bronchitis, pyelonephritis and prostatitis. Fourth-
generation compounds (e.g., gatifloxacin, moxifloxacin, trovafloxacin) exhibit a further 
enhancement of activity against a still wider range of bacterial pathogens, expanding their 
therapeutic indications further, including penicillin- and cephalosporin-resistant pneumonias (9, 
98, 141). However, despite this increased spectrum of activity and greater in vitro potency, FQs 
as a class have been associated with a number of significant adverse effects, which has resulted 
in a lack of FQ use as primary therapeutics for many indications (98, 101, 141, 153, 154).  
Currently, further structural modifications aimed at improving their pharmacokinetic (PK) 
properties and reducing adverse reactions are being investigated, and some later fourth-
generation FQs (e.g., gemifloxacin) exhibit significant reductions in adverse effects (9). 
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Figure 1.1. Prototypical fluoroquinolone structure 
 
The structure of ciprofloxacin is shown indicating the two ionizable groups of FQs: the 
piperizinyl ring nitrogen (cation) and the carboxylic acid (anion) group.  A fluorine atom (F) is 
shown at position 6. (Adapted from manuscript published in Expert Opin Drug Metab Toxicol. 
May 2012; 8(5): 553-69) 
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1. B. ACTIVE TRANSPORT AND FLUOROQUINOLONE DISPOSITION  
Despite being rapidly absorbed after oral administration, FQs exhibit a fairly broad range 
in oral bioavailability, from around 55% to greater than 90% (65, 121).  Literature has suggested 
that FQs exist primarily as ionic species in the physiological pH range (Table 3.5, 3.6), including 
at the more acidic pH values as found in the gastrointestinal (GI) tract (29). Therefore, passive 
diffusion across the GI epithelium and other systemic tissue barrier epithelia should be a 
negligible component of their overall absorption, distribution, and elimination, making it likely 
that active transport and facilitated diffusion mechanisms are involved. Recently, a number of in 
vivo and in vitro studies have pointed towards the involvement of members of the ATP Binding 
Cassette (ABC) and Solute Carrier (SLC) transporter families in the handling of FQs (see 
Section 1.3) (4, 165, 186). Most FQs are eliminated primarily by renal excretion (Table 3.2), and 
secretion into the gastrointestinal lumen, hepatobiliary excretion, and hepatic metabolism 
represent important elimination routes for only a few of these agents (67, 121). Known hepatic 
metabolism involves CYP450-mediated oxidation (desmethylation and N-oxidation) and 
glucuronidation (4, 141). Hepatobiliary excretion of these metabolites can lead to enterohepatic 
recirculation, resulting in increased residence time and terminal elimination half-life, similar to 
the effect of co-administration of probenecid or cimetidine on renal FQ elimination (see Section 
1.C). However, the circulating metabolites are thought not to contribute to the clinical 
antimicrobial efficacy, and no clinically significant metabolic drug-drug interactions have been 
identified.  
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1. C. EARLY IN VIVO AND IN VITRO DISPOSITION STUDIES INDICATING 
TRANSPORTER-MEDIATED FLUX OF FLUOROQUINOLONES 
Investigations in humans with ciprofloxacin and temafloxacin, compounds exhibiting minor 
biliary excretion, found that after intravenous administration as much as 18% of the dose 
appeared in the feces, indicating an apparent intestinal secretory component (52, 151, 152).  
Later studies in rats confirmed intestinal secretion of parenterally administered ciprofloxacin, 
fleroxacin, and sparfloxacin, and demonstrated that co-administration of ciprofloxacin or 
pefloxacin significantly reduced the in vivo intestinal clearance of ofloxacin, suggesting a 
common transport system (132, 135). Subsequent inhibition of in vivo intestinal elimination of 
ofloxacin by verapamil and quinidine indicated possible involvement of the ABC transporter 
family, e.g., MDR1, in this process (132). In vitro studies conducted in Caco-2 cell monolayers, 
a model system for human intestine, demonstrated verapamil-sensitive secretion of grepafloxacin 
and sparfloxacin, also pointing to ABC transporter involvement in the intestinal secretion of FQs 
(23, 205). Such transporter-mediated secretion from the systemic circulation into the gut lumen 
may contribute to the therapeutic efficacy of certain FQs in the treatment of GI infections such as 
bacterial diarrhea. 
A number of in vivo PK studies in humans have examined the effects of co-administration of 
cimetidine or procainamide, known inhibitors of the ‗classical‘ renal organic cation transport 
system, on the renal secretion of FQs: Co-administration of cimetidine inhibited (~13-28%) the 
renal clearance of enoxacin, fleroxacin, gemifloxacin, and temafloxacin (1, 111, 146, 149). 
Conversely, concomitant administration of ciprofloxacin, levofloxacin, or ofloxacin decreased 
procainamide renal clearance (10, 103). Furthermore, it has been reported that co-administration 
of probenecid, the prototypical inhibitor of the ‗classical‘ renal organic anion transport system, 
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significantly decreased (by ~25-60%) the renal clearance of ciprofloxacin, enoxacin, fleroxacin, 
gatifloxacin, gemifloxacin, levofloxacin, and norfloxacin in healthy volunteers (38, 42, 52, 75, 
95, 119, 142, 144, 149, 159, 197, 198). This unique clinical footprint of interaction with both the 
renal organic cation and organic anion transport systems is thought to be due to the zwitterionic 
nature of these molecules (Figure 1.1 and Tables 3.5 and 3.6). Such drug-drug interactions have 
been confirmed in rats as well, where the renal clearance of ofloxacin, which exhibits 80-95% 
recovery in urine after oral dosing, was significantly reduced upon co-administration of either 
probenecid (~50%) or cimetidine (~70%) (39). Thus, despite renal secretion of FQs being well 
established as a major pathway for their elimination, the specific in vivo molecular mechanisms 
involved in their disposition have remained unclear. 
Parallel in vitro studies conducted in renal cell lines also supported involvement of both 
organic cation and organic anion transporters in renal FQ handling: For example, the apical 
efflux from levofloxacin-loaded LLC-PK1 cells (derived from the porcine kidney) was 
significantly stimulated by an inwardly directed H
+
 gradient, suggesting a role for the renal brush 
border H
+
/organic cation antiport system in FQ elimination (124). However, cimetidine failed to 
inhibit basal uptake of levofloxacin in LLC-PK1 cells. On the other hand, in the opossum kidney 
cell model, enoxacin, grepafloxacin, and levofloxacin, each significantly inhibited the basal 
accumulation of para-aminohippurate, the prototypical organic anion transport system substrate 
(106). Furthermore, both levofloxacin and probenecid caused a significant inhibition of para-
aminohippurate efflux across the apical membrane (106). 
Recently, the cloning of hundreds of genes coding for transport proteins has made it possible 
to perform studies examining FQ interaction with known transporters selectively expressed in in 
vitro cell culture models; either by molecular identification of the transporters expressed in the 
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cell culture model (e.g., Caco-2 cells) or via establishment of transfected cell lines expressing 
specific transporters. Results from these types of studies investigating the involvement of ABC 
and SLC transporter family members are summarized in the following sections. 
1. D. ATP BINDING CASSETTE (ABC) TRANSPORTERS AND DISPOSITION OF 
FLUOROQUINOLONES 
The human ABC superfamily currently consists of 49 identified transporter proteins 
organized into 7 separate gene families (A-F; species differences do exist) (190). As their name 
implies, ABC transporters are able to directly utilize cellular energy by binding and hydrolyzing 
ATP, using the released energy to drive unidirectional transport (efflux) of substrate molecules 
across cell membranes (4). Due to their action as ‗efflux pumps‘, a number of ABC transporters 
are linked to multidrug resistance. To date, members of the ABCB, ABCC, and ABCG families 
have been implicated in FQ disposition (Figure 1.2). In human RPTCs, there is evidence for 
protein expression and function for multidrug resistance protein 1 (MDR1, ABCB1; also known 
as P-glycoprotein), multidrug resistance associated protein 2 (MRP2, ABCC2), MRP4 (ABCC4), 
and breast cancer resistance protein (BCRP, ABCG2) (Figure 1.2). ABC transporters mediate the 
movement of a wide range of molecules including lipids, peptides, nucleosides, and xenobiotics 
ranging from less than 200 Da to about 1900 Da (140). 
Concerning MRP1 (ABCC1), although transfection studies with polarized LLCPK-1 cells 
have demonstrated the basolateral membrane localization of human MRP1, its localization in 
human RPTCs has not been demonstrated (35, 85). However, if basolateral targeting is assumed, 
the efflux pump activity of MRP1 would potentially reduce the uptake of FQs from the systemic 
circulation and aid reabsorptive flux from the urine (Figure 1.2). In support of this hypothesis, 
ofloxacin was found to inhibit MRP1 activity in over-expressing human leukemia cells (178).  
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Further, the efflux of grepafloxacin was enhanced in MRP1 transfected LLCPK-1 cells (136).  
There are also a number of additional MRP family members for which renal mRNA expression 
has been reported, but no functional or protein expression data are available, and it is possible in 
the future that additional MRPs may be identified that could contribute to basal FQ efflux in 
RPTCs. 
MDR1 is expressed in the apical membrane (Figure 1.2) and mediates the efflux of substrates 
into the urine (179). When its transport function was examined in polarized LLCPK-1 or MDCK 
(derived from canine kidney) cells transfected with MDR1, enhanced secretory transport and/or 
inhibition of transporter activity by grepafloxacin, levofloxacin, and sparfloxacin was observed 
(28, 74, 120). Further, studies utilizing Mdr1 knockout mice reported increased plasma 
concentrations and decreased urinary clearance of grepafloxacin, as well as significantly 
enhanced CNS permeation of sparfloxacin (28, 136). Apical expression of BCRP (Figure 1.2), 
coupled with increased inhibitable secretory flux of ciprofloxacin, grepafloxacin, norfloxacin, 
and ofloxacin across BCRP expressing MDCK cell monolayers, suggest a role for this 
transporter in renal FQ secretion (5, 69, 107). In support of this hypothesis, Bcrp knockout mice 
were found to have significantly elevated kidney tissue levels of ciprofloxacin and grepafloxacin 
as compared to wildtype, as well as significantly increased plasma concentration of 
ciprofloxacin, after both oral and intravenous dosing (5, 107). Both MRP2 and MRP4 have been 
localized apically in human RPTCs (Figure 1.2), but investigations into FQ handling by these 
two transporters have not been reported (139, 185). However, studies in Eisai-hyperbilirubinemia 
rats, which are naturally Mrp2 deficient, demonstrated decreased biliary excretion of 
grepafloxacin, suggesting a role for Mrp2 in FQ disposition (137). Further, experiments with a 
murine macrophage model found that significantly increased protein expression of Mrp2 and 
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Mrp4 correlated with ciprofloxacin-resistance, but only knockdown of Mrp4 expression resulted 
in reversal of the resistance phenotype. Thus, it is likely that MRP2 and MRP4 contribute to FQ 
secretion in human RPTCs.  
These in vitro studies have provided considerable evidence to support the ABC transporter 
mediated flux of FQs in the body. However, for the purpose of this dissertation, the SLC-
mediated transport of these agents will be highlighted further. 
1. E. SOLUTE CARRIERS AND DISPOSITION OF FLUOROQUINOLONES: 
1.E.1 Introduction to SLC mediated transport of ionic species: 
SLCs are another class of membrane transporter proteins that mediate the movement of 
organic substrate molecules across barrier epithelia. The human SLC superfamily of transporters 
is currently proposed to be comprised of 55 separate gene families encompassing 362 identified 
transporter proteins (species differences do exist) (61). Presently, there is substantial evidence 
implicating members of the SLC22 (organic cation/anion/zwitterion transporters) and SLC47 
(MATE) families in the renal handling of FQs. The SLC22 family (26 identified members) 
includes the organic cation transporters (OCTs and OCTNs), which handle mainly cationic and 
zwitterionic organic molecules, and the organic anion transporters (OATs), which mainly 
transport anionic and zwitterionic organic molecules (Figure 1.2) (164, 165, 186, 201). The 
SLC22 family members OCT1 (SLC22A1), OCT2 (SLC22A2), OCT3 (SLC22A3), OAT1 
(SLC22A6), and OAT3 (SLC22A8) are expressed in the basolateral membrane of RPTCs and in 
vivo serve to mediate the accumulation of substrate molecules from the blood into RPTCs 
(Figure 1.2) (91, 165, 186). In the apical membrane OCTN1 (SLC22A4) and OCTN2 
(SLC22A5) likely mediate the efflux of substrate molecules from the RPTCs into the urinary 
space, whereas OAT4 (SLC22A11) and URAT1 (SLC22A12) have been proposed to mediate 
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reabsorption of substrates from the urine into RPTCs (Figure 1.2) (91, 165, 186). The SLC47 
multidrug and toxin extrusion transporters (MATEs; 2 identified members) mostly interact with 
cationic and zwitterionic molecules (175, 177). While both MATE1 (SLC47A1) and MATE2 
(SLC47A2) are found in the apical membrane of human RPTCs, only eight of the identified 
SLC22 family members are conclusively known to function in this tissue (Figure 1.2) (165, 175, 
186).   
The existence of the SLC superfamily of drug transporters was first surmised during the 
study of the physiological functioning of the primary elimination organs – liver and kidney 
(165). The renal elimination of visible charged organic molecules such as indigo carmine and 
phenol red following oral administration, led to exhaustive studies to comprehend the potential 
renal physiological mechanisms causing the removal of these species from the blood into the 
urine (165). This allowed generation of detailed renal proximal tubule cell (RPTC) models, 
explaining the potential processes resulting in secretion of organic anion and cations into the 
urine (165). It was later concluded that these processes may be mediated by specialized 
membrane proteins (165). Such initial physiological observations were the basic foundation for 
the subsequent cloning and functional characterization of individual transporter proteins within 
the different transporter families.  
As all the barrier epithelia in the body, including the RPTC, are polarized, the driving forces 
governing the trans-cellular entry and exit of charged molecules are very different (165, 201). 
Thus understanding of these physiological mechanisms is important, in order to assess 
localization of the identified transporters in these barrier epithelial models, and furthermore, 
accurately determine the transport mechanisms involved in the overall flux of ionic species (e.g., 
renal secretion in case of RPTC) (165, 201). The progress in cloning of individual transporters in 
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the barrier epithelia, and intensive in vitro studies demonstrating their functions in heterologous 
expression systems, revealed that the earlier opinions regarding transcellular movement of ionic 
species were, in fact, oversimplified (165). It was demonstrated by such in vitro studies that 
multiple transporter paralogs of each gene family could mediate the cellular entry and 
subsequent exit of charged molecules (165). It was also revealed that transport pathways for 
organic anions and organic cations, were not mutually exclusive, and that some molecules such 
as zwitterionic substrates (e.g., FQs) could be transported by either OATs, OCTs or even both 
systems, to determine their overall flux (Figure 1.1 and 1.2) (93, 138, 165). Moreover, the 
identified transporters exhibited considerable overlap in substrate (xenobiotics and endogenous 
molecules) specificities, e.g., the organic anion/cation/zwitterion transporter (Slc22) family has 
overlapping substrate specificities with organic anion transporting polypeptide (OATP; Slc21), 
multidrug and toxin extrusion (MATE; Slc47), and the ATP-binding cassette (ABC; Abc) 
families of transporters (46, 165). With the developments in transport literature, experimental 
evidence has now confirmed that organic ionic substrates can potentially enter the cell via 
OCTs/OATs/OATPs and exit via OCTN/ MATE/ABC transporters: this has introduced a whole 
new concept of substrate ‗crossover‘ (Figure 1.2) (46, 165). In addition to this, a number of 
single nucleotide polymorphisms (SNPs) in multiple transporter gene families (e.g., OCTs, 
OATPs), that affect their degree of activity, and subsequently substrate PK, have been identified 
(71, 173, 180). Such advancement in scientific knowledge concerning active transporters 
mediating in vivo flux of organic ionic xenobiotics and endogenous molecules, has indeed 
increased complexities in the physiological pathways governing their ‗net‘ PK (46, 73, 165). 
This has thus introduced a new challenge for accurate prediction of biologically relevant 
(mechanistic) models demonstrating the ‗net‘ transport of charged molecules. 
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Figure 1. 2. Proposed renal proximal tubule cell model, illustrating drug transporters and 
pathways involved in fluoroquinolone disposition   
The figure shows potential transport mechanisms and pathways involved in the renal elimination 
of FQs. FQs which exist predominantly as zwitterions and anions in blood (pH 7.4), may enter 
renal proximal tubule cells via the action of basolateral uptake transporters such as organic anion 
(OAT1 and 3) and organic cation (OCT1, 2 and 3) transporters. Cellular exit into the urinary 
space via apical efflux transporters may involve organic cation (OCTN1 and OCTN2), multidrug 
and toxin extrusion (MATE1 and MATE2), and/or ATP-binding cassette (MDR1, BCRP, MRP2, 
and MRP4) transporters. Finally, FQs may be excreted in the urine, or subjected to active 
reabsorption mediated by uptake transporters expressed in the apical membrane, such as the 
organic anion transporters OAT4 and/or URAT1. Note: Expression and basolateral localization 
of OCT1 in human RPTC is still controversial, although this has been confirmed for the rat 
ortholog of Oct1. FQ transport by organic anion transporting polypeptide 4C1 (OATP4C1) is 
currently unexplored; however, the related transporter OATP1A2 (which is not expressed in 
human RPTCs) has been implicated in intestinal FQ transport. The potential role of human 
MRP1 transport in the efflux of FQs from the cell back into the bloodstream (due to its 
basolateral localization) has yet to be explored.  FQ
-
, FQ
+
, and 
-
FQ
+
 denote anionic, cationic, and 
zwitterionic FQ microspecies, respectively. (Adapted from manuscript published in Expert Opin 
Drug Metab Toxicol. May 2012; 8(5): 553-69) 
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1.E.2 SLC transporter family mediating disposition of fluoroquinolones:  
SLC transport function is indirectly coupled to cellular energy, using the energy stored in 
concentration gradients and/or the membrane potential as driving force. Although hepatic 
expression of hOCT1 is well accepted, its renal expression and localization still remains 
controversial (80, 91, 180). However, localization of the rat Oct1 ortholog to the basolateral 
membrane in the RPTCs was demonstrated (80). Nevertheless, potential interactions of 
OCT1/Oct1 with the FQs have yet to be explored in detail. Due to its basolateral membrane 
targeting and membrane potential-sensitive mechanism of action, OCT2/Oct2 is established as an 
influx carrier mediating the movement of substrates from the renal circulation into the cytoplasm 
of RPTCs (115, 167, 170). Accordingly, the inhibition of hOCT2-mediated transport in 
transfected cells by grepafloxacin, levofloxacin, and moxifloxacin suggests that renal FQ 
elimination may be due to the action of this transporter (72, 125). While OCT3/Oct3 also has 
been demonstrated to function as a facilitated-diffusion carrier, mediating the RPTC 
accumulation of substrates from the blood, interaction of this transporter with FQs remains 
unexplored (82).  
Both OAT1/Oat1 and OAT3/Oat3 are basolateral organic anion/dicarboxylate exchangers 
that utilize the outwardly directed endogenous α-ketoglutarate gradient to drive RPTC uptake of 
subtrates from the systemic circulation (20, 115, 166, 168, 169, 171). A recent study with stably-
expressing cell lines demonstrated that ciprofloxacin is a substrate for mOat3, and has moderate 
interactions with hOAT3; while this FQ did not demonstrate significant interactions with 
hOAT1/mOat1 (187). Also, norfloxacin, ofloxacin, and gatifloxacin each exhibited a 
concentration-dependent inhibition of mOat3-mediated transport (187). Furthermore, 
experiments in Oat3 knockout mice using clinically relevant ciprofloxacin concentrations 
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demonstrated that the in vivo effect of transporter deletion is similar to the reported effect of 
concomitant probenecid administration on FQ disposition in humans (187). 
It is of note that, although RPTC influx of FQs via hOATP4C1 (SLCO4C1) has not been 
reported, it should be investigated in the future (Figure 1.2). This is based upon a report 
identifying the related transporter, hOATP1A2 (SLCO1A2), as mediating accumulation of 
levofloxacin and likely being responsible for the high-affinity uptake component for levofloxacin 
identified in Caco-2 cells (100). hOATP1A2-mediated uptake of ciprofloxacin, enoxacin, 
gatifloxacin, lomefloxacin, and norfloxacin were also observed (100). 
Apical RPTC membrane localization coupled with an organic cation/H
+
 exchange 
mechanism properly situates OCTN1/Octn1 and OCTN2/Octn2 as potential efflux pathways for 
FQs (174, 203, 204). While direct OCTN1/Octn1-mediated transport of FQs has not been 
demonstrated, both levofloxacin and ofloxacin produced significant inhibition of 
tetraethylammonium transport in OCTN1-expressing cells, suggesting this transporter may play 
a role in renal FQ secretion (204).  Evidence for OCTN2 interaction with FQs is also somewhat 
indirect, as it was investigated as inhibition of carnitine transport in a Caco-2 cell isolate found to 
express OCTN2, but not OCTN1 (62). In these Caco-2 cells, both levofloxacin and grepafloxacin 
produced significant inhibition of carnitine uptake, supporting involvement of OCTN2 in both 
intestinal absorption and RPTC efflux of FQs (62). 
The apical efflux and reabsorption of small organic anions into and out of the urinary space 
still remains somewhat poorly understood. Early studies with apical membrane vesicles 
supported both a facilitated diffusion mechanism (efflux) and an anion exchange mechanism 
(uptake or efflux depending upon energetics) (164, 165, 186). Despite being immunolocalized to 
the apical RPTC membrane, the mechanism of hOAT4 action also remains clouded, as 
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conflicting data indicating it is a facilitated diffusion carrier and an exchanger were reported (15, 
32, 57).  Further complicating the issue is debate over whether the exchange mechanism drives 
efflux from the RPTCs or the reabsorption of compounds from the urinary space into RPTCs.  
Currently, there are no studies investigating the interaction of FQs with hOAT4 and its potential 
role in the secretion and/or reabsorption of FQs remains unknown. Finally, hURAT1/Urat1 
localization to the apical membrane of RPTCs and its function as an organic anion/urate 
exchanger are consistent with its mediating the efflux of organic anions from RPTCs into the 
urine in exchange for certain substrate molecules such as urate (33). Whether FQs can substitute 
for urate and, thus, be actively reabsorbed from the urinary space by URAT1 remains 
uninvestigated. 
The transporters hMATE1/Mate1 and hMATE2/Mate2 represent mammalian orthologs of 
bacterial transporters demonstrated to confer resistance to FQ therapy (13). Although MATE1 
and MATE2 were initially identified in the same study, only MATE1 was functionally 
characterized and found to operate as an organic cation/H
+
 exchanger targeted to the apical 
membrane of RPTCs (Figure 1.2) (127). The rat ortholog of MATE1 was reported to transport a 
number of FQs including ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, and norfloxacin 
(123). The function and membrane targeting of MATE2 has not been reported. However, what 
appears to be a kidney-specific splice variant of MATE2, sometimes referred to as MATE2-K, 
has been examined. This variant contains a 108 basepair deletion in Exon7 resulting in the loss 
of 36 amino acids in the length of the protein product, but it still shares 94% amino acid identity 
with the full-length MATE2 isolate (105). Functional analysis confirmed it operates as an 
organic cation/H
+
 exchanger and is likely targeted to the apical membrane, however the antibody 
used to establish localization would recognize both the full-length and truncated MATE2-K 
  
16 
 
forms (105).  Levofloxacin and ciprofloxacin were found to be potent inhibitors of the MATE2K 
variant (175). 
1. F. FLUOROQUINOLONE-ASSOCIATED ADVERSE EFFECTS 
Although the FQs have been used extensively for a wide array of infections down the years, 
there have been several mild-to-severe adverse events observed on their clinical use in patients.  
The most common adverse effects associated with these agents range from mild effects on the 
gastrointestinal tract such as nausea, vomiting, and diarrhea, to moderate or severe phototoxicity, 
to extremely serious CNS effects including seizures, anxiety, and toxic psychosis (98, 101, 141, 
153, 154). A number of other rare adverse events have been reported including severe renal 
(crystalluria, interstitial nephritis, hemolytic-uremic syndrome, and acute renal failure) and 
hepatic toxicities, cardiac effects, hypoglycemia, and tendon rupture (98, 101, 141, 153, 154).  
These toxicities are generally associated with higher serum, tissue, and urinary FQ 
concentrations, resulting from their prolonged presence in the body. As a result, several FQs had 
to be withdrawn from the U.S. market. For example, temafloxacin was removed from the market 
soon after its approval due to high instances of hemolysis and renal failure (122, 154).  
Trovafloxacin was linked to severe hepatotoxicity in over 100 patients, sometimes resulting in 
hepatic necrosis and acute hepatic failure (154). Cardiac effects including tachycardia, 
prolongation of the QTc interval, and onset of torsades de pointes, including fatalities, have been 
observed with a number of FQs including levofloxacin, moxifloxacin, sparfloxacin, gatifloxacin, 
and grepafloxacin; this cardiac risk contributed to the withdrawal of the latter three (8, 141, 154).  
Ciprofloxacin, moxifloxacin, and pefloxacin have been associated with tendinitis and tendon 
rupture in patients of all ages (84, 101, 154). Incidences of tendon injury became so prevalent 
that in 2008 the FDA issued a class label change for a Boxed Warning for increased risk of 
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tendinitis and tendon rupture. Also more recently, in 2011, the FDA issued yet another class 
label change for a Boxed Warning for increased risk of FQ-associated exacerbation of 
Myasthenia Gravis.  Although most FQ-associated adverse effects occur only rarely, FQs have 
been prescribed with caution. Due to these adverse events, and their known elimination routes, 
FQs need to be administered with caution, and suitable dosage adjustments need to be conducted 
for some FQs depending on the clinical scenario and patient kinetics (88, 155). Also, as most of 
these rare adverse events occur due to complex mechanisms which still have to be studied in 
detail, it has become essential to study the PK of these agents to prevent their accumulation due 
to any pre-existing condition (e.g. renal impairment), or any potential drug interaction. Thus, a 
more complete understanding of the molecular mechanisms underlying these adverse effects, 
including the potential contribution of transporter proteins to their PK behavior and target organ 
toxicities is critical.  
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CHAPTER 2 
RESEARCH HYPOTHESES AND SPECIFIC AIMS 
 
 
 
 
2. A HYPOTHESES: 
 
2.A.1 For fluoroquinolones (FQ) excreted unchanged in urine, in addition to passive glomerular 
filtration, active transport systems are involved in their renal tubular secretion and/or 
reabsorption.  
2.A.2 Due to the zwitterionic nature and small molecular size of these molecules, members of 
the Solute Carrier (SLC22) transporter family, i.e., organic anion (OATs) and organic cation 
(OCTs) transporters, are likely to be involved in renal elimination of the FQs. 
2.A.3 For at least some SLC22 family members, the PK interactions with the FQs will prove to 
be clinically significant. 
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2. B SPECIFIC AIMS TO ADDRESS THE ABOVE HYPOTHESES:  
2.B.1. SPECIFIC AIM 1. 
A systematic review of FQ biomedical literature will allow identification of FQs 
demonstrating sufficient PK information to further evaluate their disposition mechanisms – 
i) Systematic review: to compile and calculate the PK parameters from clinical literature 
focusing on ‗healthy human adult‘ population for the FQs and assess their ‗renal 
elimination‘ component; estimate the PK parameter: renal tubular clearance (CLren,tub).  
ii) To conduct a statistical analysis of the PK parameters and evaluate for the existence of a 
trend explaining differences in the in vivo PK profiles of the FQs. 
iii) From the above analysis, identify the net renal elimination processes responsible for the 
excretion of the FQs. 
iv) To compile and analyze the physicochemical properties of the FQs and identify suitable 
physicochemical characteristics suggestive of interaction with members of the organic 
anion/cation/zwitterion transporter family (SLC22).   
 
2.B.2. SPECIFIC AIM 2. 
To test the hypothesis that members of the organic anion/cation/zwitterion (SLC22) 
transporter family impact the observed CLren,tub
 
for identified FQs –  
 
i) Literature has suggested that organic anion (OATs: hOAT1/mOat1, hOAT3/mOat3) and 
organic cation (OCTs: hOCT1, hOCT2 and hOCT3) transporters of the SLC22 family are 
localized on the basolateral membrane of RPTC. Initial preliminary studies using stably 
transfected cell lines, will be conducted for selected FQs identified in the systematic review, 
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to detect any significant interactions of these agents with the transporters. Further, transporter 
based kinetic experiments will be conducted to examine inhibition constants (Ki values) or 
half maximal inhibition concentrations (IC50 values) of FQs for these transporters. These 
studies will involve an investigation of the role of these basolateral transporters in renal 
uptake of FQs from blood to RPTC, i.e., the first step to renal elimination of the FQs. 
ii) Among the SLC transporters, hOAT4 is known to be localized on the apical membrane of 
RPTC. FQs identified in the systematic review will be tested in preliminary studies using 
stably transfected cell lines, to investigate any significant interaction with this transporter. 
This will be followed by conducting kinetic experiments to investigate the inhibition 
potencies of any strong inhibitors. These studies will aim to identify hOAT4 as a potential 
reabsorptive transporter for the FQs in the RPTC, i.e. mediator for the FQs to enter the RPTC 
back from the urinary space. 
As a summary, for each transporter, the following transport studies will be conducted with stably 
transfected cell lines, using FQs as inhibitors: 
a) Preliminary screening study of the FQs identified from Specific Aim 1 to detect any 
significant drug transporter interactions. 
b) To determine the linearity of transport (time course), and conduct concentration-
dependency studies to estimate the Km of prototypical substrates for individual 
transporters, and IC50 values for the FQs demonstrating significant inhibition in 
preliminary inhibition studies. 
c) To assess the mode of inhibition (competitive/non-competitive/uncompetitive) for the 
FQs, followed by determination of their inhibition constants (Ki value). 
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2.B.3. SPECIFIC AIM 3. 
To study the impact of OATs and OCTs towards the observed in vivo renal clearance for 
the studied dataset of FQs: 
The ratios of the ‗unbound Cmax/IC50 (or Ki)‘ for the individual FQs will be calculated for each 
transporter (OAT and OCT) according to the recommendation in the FDA‘s recent drug-drug 
interactions  (DDI) guidance for assessing transporter impact in clinically relevant DDI with FQs 
will be further analyzed.  
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CHAPTER 3 
 
QUANTITATIVE PHARMACOKINETIC SYSTEMATIC REVIEW OF 
FLUOROQUINOLONES ADMINISTERED IN HUMANS 
Drawn from manuscript published in Expert Opin Drug Metab Toxicol. May 2012; 8(5): 553-69 
 
 
 
 
3. A SYSTEMATIC REVIEW OF FLUOROQUINOLONES 
The FQ antimicrobials possess very similar structural scaffolds and physicochemical 
characteristics; yet, they exhibit a wide range of pharmacokinetic (PK) properties. Historical 
clinical PK literature and recent in vitro disposition studies have implicated the involvement of 
active transport mechanisms in renal handling of FQs, which accounts for one of the primary 
elimination pathways of these antibiotics (see Chapter 1). Therefore, the intent of this systematic 
review was to compile published human in vivo PK properties for FQs and to assess any 
relationships between pertinent, biologically relevant systemic PK variables and possible renal 
active transport mechanisms. 
The analysis involved initial identification and review of FQ-related biomedical literature, 
which was then refined to articles pertaining to PK and urinary excretion studies in healthy 
human subjects. Once the studies were identified, they were carefully examined according to the 
inclusion criteria set-up for the analysis (as described ahead). These encompassed studies 
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specifically focused on healthy adult human subjects (between 18-60 years of age) within the 
normal weight range, i.e., depending on their body mass index wherever specified. The study did 
not set specific inclusion criteria for gender of the subjects. The patients were evaluated for 
overall good health before the study on the basis of medical history, physical examination, and 
laboratory evaluation procedures. In some FQ studies including different patient treatment-
groups, (e.g., healthy volunteer groups along with groups of patients suffering from renal or 
hepatic impairment, or specific bacterial infections), only data from the healthy volunteers was 
considered after a careful assessment of their age, weight and organ functioning. Specifically, in 
some studies where the kidney function of the volunteers was assessed by measuring creatinine 
clearance, only the PK data of groups showing creatinine clearance ≥ 80 ml/min was considered 
for the analysis. The patients were required to be non-smokers and non-alcoholics (these 
conditions were assumed whenever not mentioned in the studies).   
This review for FQs preferably included PK studies with intravenous (IV) route of 
administration (Table 3.2). For some of the FQs where the IV studies were not available, oral 
studies were considered for the analysis. However, in these oral studies, only apparent systemic 
volume of distribution and systemic/total clearance values were available, which were influenced 
by individual bioavailabilities (Foral) of the FQs, and hence were not compiled. Essentially only 
single-dose studies were considered for this analysis. Linear PK was the main assumption for 
interpretation of all compiled PK parameters for the identified FQs. To assess this assumption for 
the identified FQs, repeated dose escalation and multiple dose studies were compiled, and the 
‗PK metrics‘, namely, average concentrations achieved at steady state (Cssave), maximum and 
minimum concentrations on the concentration-time curve (Cmax) and (Cmin), and area under the 
concentration-time curve from zero time-point to infinity (AUC∞: usually calculated by 
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trapezoidal rule in the studies), were analyzed for dose-related change (7, 31, 40, 43, 49, 51, 56, 
176, 191, 192, 196). In these studies, the concentrations, (i.e., C
ss
ave, Cmax, Cmin) and the AUC∞ 
were found to increase dose-proportionally, while, the volume of distribution at steady state 
(Vdss) essentially remained constant with increase in dose. These observations thus confirmed 
that FQs would follow linear PK in the clinically administered doses, and thus linear PK was 
assumed for further calculations of PK parameters, discussed ahead in this chapter (134). In all 
the studies, the urine as well as blood sampling schedules were critically evaluated to optimize 
the urinary excretion and concentration-time curves for further PK analysis (the extrapolated 
AUC from the last sample point to infinity was usually not more than 20 % of the total AUC∞).  
The final database for all the FQs encompassed representative compounds from the second 
(n=9), third (n=4), and fourth (n=5) generations. Systemic pharmacokinetic properties were 
compiled for both intravenous and oral studies of the FQs. Pharmacokinetic variables included 
total body clearance (CLtot), renal clearance (CLren), non-renal clearance (CLnonren, which was 
obtained for FQs with available intravenous data only), Vdss, terminal half-life (t1/2) and fraction 
excreted unchanged in urine (fe) (Table 3.1 and 3.2). When not provided in the original 
references, CLren was calculated by: CLren = U∞/AUC∞ (U∞, amount excreted in urine from zero 
to infinity) (Table 3.1 and 3.2). If the studies did not report body weight (BW) corrected PK 
parameters, then the parameters were corrected for BW using mean BW of the subjects in the 
study. In cases where BW was not mentioned, a BW of 70 kg was assumed (41). The fraction 
unbound in plasma (fu) was obtained from in vitro protein binding studies conducted using 
human plasma (Table 3.2) (64, 145, 161, 208). The plasma-protein-binding-corrected 
pharmacokinetic variables, namely unbound volume of distribution (Vdss
u
) and unbound total 
(CLtot
u
), nonrenal (CLnonren
u
) and renal (CLren
u
) clearances, were further calculated using fu (Table 
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3.1 and 3.2). Finally, a new term - defined as ‗net renal tubular clearance‘ (CLren,tub) - was 
calculated by: CLren,tub = CLren
u
 – glomerular filtration rate (GFR, assumed to be 1.6 ml/min/kg); 
a negative value indicates net tubular reabsorption, while a positive value indicates net tubular 
secretion. This CLren,tub variable, quantifying the contribution of renal tubular reabsorption and/or 
secretion, was used to categorize the FQs examined in this study (n=18) into three groups 
according to their differences in renal tubular handling (Figure 3.1, Tables 3.1, 3.2 and 3.4).  
Group 1 represents those FQs undergoing net tubular reabsorption (defined as CLren,tub < -1 
ml/min/kg), Group 2 includes FQs identified as having little or no net tubular transport (defined 
as -1 ≤ CLren,tub ≤ 1 ml/min/kg), and Group 3 contains the FQs exhibiting net tubular secretion 
(defined as CLren,tub > 1 ml/min/kg) (Table 3.1 and 3.4). 
Relevant physicochemical properties (Tables 3.5 and 3.6), such as molecular weight, 
hydrogen bond donors (HBD), hydrogen bond acceptors (HBA), number of rotatable bonds 
(nRot), molar volume, logarithmic value of the FQ distribution coefficient (log D), pKa and 
percent ionization were obtained for all the FQs (except Antofloxacin, as physicochemical data 
was unavailable through the software) using SciFinder Scholar (2010) and ACD/PhysChem 
Suite (Advanced Chemistry Development, Inc.). 
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Table 3.1. Calculated pharmacokinetic properties for the fluoroquinolones 
PK property Formula 
Vdss
u 
Vdss / fu 
CLtot
u 
CLtot / fu 
CLren U∞/AUC∞ 
fe CLren*100 / CLtot 
CLren
u 
CLren / fu  
CLnonren CLtot  - CLren 
CLnonren
u 
CLnonren / fu  or CLtot
u 
- CLren
u 
CLren,tub
 
CLren
u – Glomerular filtration rate (assumed to be 1.6 ml/min/kg) 
CLren,tub < -1 = Net tubular reabsorption (Group 1) 
CLren,tub ≥ -1, but ≤ 1 = No net tubular transport (Group 2) 
CLren,tub > 1 = Net tubular secretion (Group 3) 
Vdss
u
: unbound volume of distribution at steady-state; Vdss: volume of distribution at steady-
state; CLtot
u
: unbound total clearance; CLtot: total clearance; CLren: renal clearance; U∞: amount 
excreted in urine from zero to infinity; AUC∞: area under the concentration-time curve from zero 
to infinity; fe:  fraction of parent drug excreted unchanged in urine expressed as %; CLren
u
: 
unbound renal clearance; CLnonren: nonrenal clearance; CLnonren
u
: unbound nonrenal clearance; 
CLren,tub: net renal tubular clearance 
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3. B   PHARMACOKINETIC PROPERTIES OF FLUOROQUINOLONES: 
The newer generations of FQs exhibit wider systemic distribution characteristics and longer 
duration of action as compared to the older compounds (11, 29, 159, 208). This may partially be 
a consequence of increased plasma protein binding, resulting in decreased elimination. For 
example, the fourth-generation FQ, trovafloxacin, shows plasma protein binding of 
approximately 76% (fu = 24%) and an elimination/terminal half-life (t1/2) of 11.2 hours, while the 
second-generation FQ, ciprofloxacin, has plasma protein binding of only 40% (fu = 60%) and a 
correspondingly shorter t1/2 of 4.2 hours (Table 3.2). However, as discussed below, differences in 
renal excretion mechanisms (CLren,tub) are likely more important for their duration of action 
(Table 3.2 and 3.4, Figure 3.1). 
The newer FQs also exhibit increased tissue penetration, allowing them to reach higher 
intracellular concentrations (159, 208). Systemically, this translates into significantly greater FQ 
levels in target organs such as the intestine, kidney, liver, lungs and prostate than in the plasma 
(68, 76, 147, 148). Bone stands out as a tissue in which FQ permeability is generally poor (44).  
FQ levels in secretions are inconsistent, with most FQs reaching concentrations in saliva, pleural 
fluid, and bronchial epithelial lining fluid that are above that measured in serum, but exhibiting 
considerable variation in sweat, tears, and blister fluids (29, 141, 147, 159). Terminal half-lives 
in the individual fluid secretions also vary, with t1/2 in the saliva being shorter than in plasma, 
while it was similar to plasma in bronchial secretions, and slightly longer in sweat, tears, and 
blister fluids (29, 141, 147, 159). With the exception of meningococcal infections, FQ 
permeation of the cerebrospinal fluid is extremely limited (48). 
Not surprisingly, urine and biliary FQ concentrations often greatly exceed those in plasma as 
a consequence of the excretory functions of the kidney and liver. Indeed, for many FQs, their 
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unchanged urinary levels are considerably higher than their minimum inhibitory concentrations 
for most urinary pathogens, explaining their therapeutic success in the treatment of urinary tract 
infections (121, 141, 149, 161, 193). Similarly, for those FQs which undergo extensive intestinal 
secretion or hepatic metabolism, the unchanged drug and metabolite concentrations in feces are 
high, rendering them effective in the treatment of many gastrointestinal infections (68, 141, 147).  
Thus, in instances where the FQs are excreted primarily unchanged by the kidneys (e.g., 
ofloxacin, levofloxacin), renal clearance is an essential component of their total body clearance 
(Table 3.2). On the other hand, in situations where FQs are removed to a large extent by hepatic 
elimination (e.g., moxifloxacin, rufloxacin), nonrenal clearance is an important determinant of 
their pharmacokinetics (Table 3.2). 
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Table 3.2. Compiled pharmacokinetic parameters from the systematic review for n=18 fluoroquinolones 
 t1/2 fu Vdss
u 
fe CLtot CLtot
u 
CLren CLren
u 
CLnonren
u 
CLren,tub
 
Group Refs. 
 
IV studies (hr) (%) (L/kg) (%) (ml/min/kg)   
Ciprofloxacin 4.2 60 3.9 50 10.3 17.0 5.1 8.4 8.6 6.80 3 (27, 64, 97, 199) 
Ofloxacin 6.6 70 -- 80 3.7 5.7 3.0 4.6 1.1 3.00 3 (99) 
Enoxacin 4.3 60 3.3 56 5.1 8.6 2.9 4.8 3.8 3.17 3 (111) 
Gatifloxacin 11.3 60 3.0 80 2.5 4.2 2.0 3.4 0.9 1.79 3 (43) 
Moxifloxacin 14.2 45 4.5 20 2.5 5.4 0.6 1.3 4.1 -0.30 2 (145, 156, 158) 
Lomefloxacin 6.4 85 2.2 56 3.3 5.6 1.9 2.2 3.4 0.59 2 (53, 160, 200) 
Levofloxacin 7.1 69 1.7 62 2.1 3.5 1.3 1.9 1.6 0.28 2 (17, 19) 
Fleroxacin 13.0 77 1.8 66 1.4 2.4 0.9 1.2 1.1 -0.39 2 (161) 
Trovafloxacin 11.2 24 5.4 11 1.4 6.0 0.2 0.7 5.3 -0.92 2 (176, 192) 
Antofloxacin 20.3 83 4.6 58 2.1 2.5 1.2 1.5 1.1 -0.12 2 (194) 
Oral studies 
Gemifloxacin 7.1 35     3.3 9.5  7.94 3 (1, 2) 
Norfloxacin 4.3 80     7.5 9.4  7.80 3 (30) 
Amifloxacin 3.6 50     1.7 3.3  1.70 3 (21) 
Temafloxacin 7.7 74     1.8 2.4  0.81 2 (50) 
Grepafloxacin 12.2 72     0.5 0.7  -0.91 2 (31) 
Rufloxacin 34.9 40     0.2 0.6  -1.01 1 (89, 131) 
Sparfloxacin 20 55     0.3 0.5  -1.13 1 (37, 112) 
Pefloxacin 8.6 75     0.4 0.5  -1.10 1 (114) 
t1/2: half-life in hr; fu: fraction of unbound drug expressed as %; Vdss
u
: unbound volume of distribution at steady-state; CLtot: total 
clearance; fe:  fraction of parent drug excreted unchanged in urine expressed as %; CLtot
u
: unbound total clearance; CLren
u
: unbound 
renal clearance; CLnonren
u
: unbound nonrenal clearance; CLren,tub: net renal tubular clearance, calculated as CLren
u 
- glomerular filtration 
rate (GFR assumed to be 1.6 ml/min/kg); Groups 1, 2 and 3 were assigned as defined in Table 3.4. For oral studies, true Vdss
u
, CLtot, 
and fe could not be obtained because only apparent values, which were influenced by the individual bioavailabilities (Foral), were 
available. Since in most instances CLnonren
u
 was calculated as CLtot
u
 – CLren
u
, this value was also excluded from the oral studies 
dataset. For parameter estimates obtained from the systematic review, the values reported are the average of mean values; therefore, 
standard deviations have not been reported (Refer to Appendix I). (Adapted from manuscript published in Expert Opin Drug Metab 
Toxicol. May 2012; 8(5): 553-69). 
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Evaluating the pharmacokinetic properties in the final database (n=18) reveals the fraction 
unbound in plasma (fu) showed a limited, 3.5-fold difference (Table 3.3) amongst the FQs; 
overall, plasma protein binding was low. Both Vdss
u
 and CLtot
u
 were fairly uniform, indicating 
that the systemic distribution and overall elimination – after correction for plasma protein 
binding – varied only moderately across FQs (Table 3.3). Generally, each FQ showed at least 
some extravascular/intracellular distribution [Vdss
u
 >> plasma (0.04 L/kg) and total body water 
volume (0.6 L/kg)], and their clearances were lower than hepatic blood flow (20 ml/min/kg), but 
exceeded GFR for some. Most notably, their CLren
u
 values showed a wide distribution with a 20-
fold difference among the compounds, illustrating that - despite being similarly distributed 
throughout the body - other factors (e.g., ionization state, renal drug transporters, see section 3.C) 
significantly influence their renal handling. Determination of the renal tubular clearance 
(CLren,tub) provides further insight as to which tubular handling process (e.g., net secretion vs. net 
reabsorption) plays the greatest role in renal elimination of each individual FQ, which further 
allows classification into FQs in Groups 1, 2 and 3 (Figure 1.2 and 3.1, Table 3.2 and 3.4). For 
these FQ groups, there were no substantial differences between CLnonren
u
, Vdss
u
 and fu, suggesting 
particular molecular properties/specific transporter interactions may account for differences in 
renal handling, but may not affect other PK properties (Table 3.3). Most importantly, it was 
found that the mean plasma half-lives (t1/2) showed significant differences between the three 
groups (Table 3.4): The t1/2 of Group 1 was significantly longer as compared to Group 3 (p < 
0.01), with the FQs in Group 1 showing a 3 to 4-fold higher t1/2 than those in Group 3, and ~2-
fold higher t1/2 than the FQs in Group 2 (Table 3.4). Values for Group 1 and Group 2, as well as 
Group 2 and Group 3 did not differ significantly. This suggests that the differences in renal 
tubular handling between the various FQs may be the major reason for their differences in 
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systemic half-life, i.e., the role/contribution of renal tubular drug transporters may be the main 
determinant for the duration of action for FQs. 
The renal tubular clearance differences of FQs between Group 1 and Group 3 (Table 3.4) 
may be explained by significant interactions of FQs with renal tubular drug transporters:  FQs in 
Group 1, wherein CLren
u
 is less than GFR, are likely to predominantly/efficiently interact with 
apically expressed transporters that mediate their (net) tubular reabsorption (Figure 1.2). Of 
course, interactions with basolateral and apical transporters in the blood to urine (secretory) 
direction in the RPTC, prior to being offset/overcome by the reabsorptive flux, are likely to 
occur as well. On the other hand, FQs in Group 3, wherein CLren
u
 exceeds GFR, are expected to 
be substrates for basolateral and apical transporters and to exhibit a substantial blood to urine 
secretory flux, i.e., net tubular secretion. Thus, the marked dispersion of CLren
u
 and CLren,tub 
values among FQs could be attributed to carrier-mediated mechanisms existing in RPTC. Such 
transporter interactions should be critically evaluated, as this may also be one explanation for 
some reported in vivo drug-drug interactions, e.g., decreased clearance of FQs co-administered 
with cimetidine or probenecid (see Chapter 1, Section 1.C). Such interactions could significantly 
affect FQ disposition kinetics and hence alter their efficacy and/or toxicity profiles. 
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Table 3.3. Summary of systemic pharmacokinetic and physicochemical properties of 
fluoroquinolones in the systematic review 
 
 Mean Range Fold difference 
Pharmacokinetic property 
Vdss
u
 (L/kg) 3.4 1.7-5.4 3.1 
fu (%) 57 24-85 3.5 
CLtot
u
 (ml/min/kg) 6.6 2.4-17.0 7.1 
CLren (ml/min/kg) 1.9 0.2-7.5 46.2 
CLren
u
 (ml/min/kg) 3.1 0.5-9.5 20.2 
CLnonren
u
 (ml/min/kg) 3.1 0.8-8.6 10.1 
Physicochemical property 
Molecular weight (Da) 369.6 319-462 1.4 
Molar volume (cm
3
) 254.3 203-300 1.5 
Log D (pH = 7.4) -0.2 -1.1-1.1 -- 
Vdss
u
: Unbound volume of distribution at steady-state; fu: Fraction of unbound drug in plasma; 
CLtot
u
: Unbound total body clearance; CLren: Renal clearance; CLren
u
: Unbound renal clearance; 
CLnonren
u
: Unbound nonrenal clearance: Da: Daltons; Log D: Logarithmic value of distribution 
co-efficient. (Adapted from manuscript published in Expert Opin Drug Metab Toxicol. May 
2012; 8(5): 553-69) 
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Table 3.4.  Characteristics used to define the groups as reported in Table 3.2 and Figure 3.1 
based on renal tubular handling and associated plasma half-lives 
 
CLren, tub Net renal handling process Group t1/2 
(ml/min/kg)   (hr) 
Negative (< -1) net tubular reabsorption 1 21.2 ± 13.1 (n=3) 
≥ -1 and ≤ 1 little/no net tubular transport 2 11.5 ± 4.6 (n=8) 
Positive (> 1) net tubular secretion 3 5.9 ± 2.7 (n=7) 
CLren,tub: estimated net renal tubular clearance; t1/2: half-life in plasma (reported as mean ± 
standard deviation). (Adapted from manuscript published in Expert Opin Drug Metab Toxicol. 
May 2012; 8(5): 553-69) 
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Figure 3.1.  Categorization of fluoroquinolones based on renal tubular clearance (CLren,tub) 
 
FQs were separated into three groups based upon their CLren,tub obtained from the 
pharmacokinetic systematic review.  FQs were assigned to groups according to the criteria listed 
in Table 3.4. (Adapted from manuscript published in Expert Opin Drug Metab Toxicol. May 
2012; 8(5): 553-69) 
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3. C. PHYSICOCHEMICAL PROPERTIES OF FLUOROQUINOLONES 
As FQs have evolved through successive generations of drug discovery, their molecular 
structures have been modified to some extent. Molecular size, molecular weight, LogD, pKa, 
molar volume, number of hydrogen bond donors, number of hydrogen bond acceptors, number 
of rotatable bonds, and microspecies (ionization) profiles at physiological pHs were estimated 
for individual FQs (Tables 3.3 and 3.4). The values reported herein were restricted to those 
eighteen FQs for which sufficient data were obtained in the systematic review to estimate 
unbound renal clearance (CLren
u
) and renal tubular clearance (CLren,tub) (See Table 3.2). No 
significant trends were detected on comparing the hydrogen bond donors, hydrogen bond 
acceptors, number of rotatable bonds, LogD (at pH 7.4), molecular weights, or molar volumes 
across the three groups (Refer Appendix II and Table 3.3). LogD values (at pH 7.4) for the FQs 
were predominantly low, indicating their largely hydrophilic nature. FQs in the final database 
had similar structural scaffoldings with two pKa values, an acidic pKa between 5.19 and 6.44 and 
a basic pKa between 6.30 and 10.63 (Table 3.3; notably, the software was unable to accurately 
predict acidic pKa values for fleroxacin, lomefloxacin, norfloxacin and pefloxacin). The close 
proximity of the two pKa values dictates that these FQs exist predominantly as zwitterions in the 
physiological pH range due to the dissociation of a carboxyl group at the 3-position of the 
quinolone ring and the protonation of the piperizinyl ring nitrogen (Figure 1.1) (9, 29).  
However, Table 3.5 suggests that ionization profiles demonstrate considerable differences 
between FQs in their proportion of anionic (A), cationic (C), neutral (N) and zwitterionic (Z) 
species at physiologically relevant pH values. For example, gemifloxacin is predicted to exist 
completely as a zwitterion at the blood pH of 7.4, while rufloxacin would show a minor 
zwitterionic component (17%) and be primarily anionic (82%), and ciprofloxacin would be 
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predominantly zwitterionic (82%), with co-existing cationic (10%) and anionic (7%) 
microspecies. However, at the urinary pH of 6.3 it is predicted that gemifloxacin will exhibit 
both zwitterionic (82%) and cationic (18%) microspecies, rufloxacin will become primarily a 
zwitterion (67%) with some anionic (21%) and cationic (5%) microspecies, and ciprofloxacin 
will be largely cationic (60%) with some zwitterionic (39%), but no anionic species. In general, 
for the FQs listed in Table 3.5, zwitterionic and anionic species are most prevalent at pH 7.4, 
whereas at pH 6.3 zwitterionic and cationic species dominate. Regardless, as FQs exist as 
charged molecules in blood and urine, their absorption, distribution, and elimination are likely to 
be influenced by active transport mechanisms in addition to passive diffusion and glomerular 
filtration. 
Prulifloxacin was specially included into the dataset for analysis of physicochemical 
properties of FQs (Tables 3.5 and 3.6), as it is the only prodrug FQ, which is currently marketed 
(alatrofloxacin, the prodrug of trovafloxacin was withdrawn due to hepatotoxicity) (81, 122). 
This prodrug is absorbed mainly from the upper small intestine, followed by hepatic first-pass 
metabolism by an α-esterase (paraoxonase) to being converted into the active FQ: ulifloxacin 
(12, 81). Hence, it was of interest to study the in vitro OCT-FQ interactions, potentially 
mediating prulifloxacin‘s GI absorption and hepatic metabolism for conversion into its active 
metabolite, ulifloxacin. This analysis predicted prulifloxacin to exist predominantly as an anion 
at the pH values of 7.4 (95%A, 3%Z) and 6.3 (55%A, 6%C, 23%N, 17%Z) (Table 3.6). Due to 
absence of in vivo studies matching our inclusion criteria for this FQ prodrug (detected as 
ulifloxacin in vivo), as well as due to unavailability of the active metabolite ulifloxacin for in 
vitro studies, no analysis has been demonstrated for ulifloxacin. However, the prodrug was 
pursued further for in vitro testing (See Chapters 4 and 5). 
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The information summarized in Tables 3.2-3.5 and Figure 3.1 may allow prioritization of in 
vitro studies designed to identify the active transporters that contribute to the renal tubular 
secretion and/or reabsorption of FQs: For example, at blood pH, sparfloxacin exists almost 
completely as zwitterionic (80%) and cationic moieties (11%), with only a small anionic 
component (8%). Furthermore, the pharmacokinetic literature indicates that co-administration of 
probenecid does not inhibit its renal clearance (143). Taken together, this suggests that a 
basolateral OCT pathway (e.g., OCT1, OCT2 and/or OCT3) mediates its accumulation in human 
RPTCs from the blood and its subsequent efflux into the urine (perhaps via an OCTN or MATE) 
(Figure 1.2). However, at urinary pH, sparfloxacin exists as cationic (63%) and zwitterionic 
moieties (36%), with no anionic species. Coupled with the lack of inhibition by co-administered 
probenecid, this suggests an unidentified apical organic cation uptake transporter mediates its 
tubular reabsorption (95, 143).  Similarly, moxifloxacin, whose renal handling is unaffected by 
probenecid (157) and has ionization profiles of 93%Z, 7%A, 0%C at pH 7.4 and 51%Z, 0%A, 
49%C at pH 6.3, may cross the basolateral membranes of human RPTCs via OCT1, OCT2 
and/or OCT3 and exit across the apical membrane via any one or all of the identified efflux 
transporters (Figure 1.2). On the other hand, for compounds predominately anionic in the blood 
such as fleroxacin (86%A, 13%Z, 0%C at pH 7.4) and levofloxacin (62%A, 37%Z, 0%C at 
pH7.4), whose renal excretion is known to be inhibited by co-administration of probenecid (38, 
81, 142), basolateral RPTC uptake is likely mediated by OAT1 and/or OAT3, followed by apical 
ATP Binding Cassette transporter mediated efflux. Hence these structural parameters and 
ionization profiles of FQs, may potentially aid in prediction of renal transport mechanisms likely 
to mediate the in vivo renal disposition of these antimicrobials (See section 1.C). 
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Table 3.5.  Physicochemical properties of the fluoroquinolones in the systematic review 
 
 MW Log D HBD
 
HBA nRot Molar Volume
 
pKa (acidic) pKa (basic)
 
Drug: (Da) (pH = 7.4)    (cm
3
)   
Amifloxacin 334 -0.7 2 7 3 231.7 6.2 ± 0.4 
 
7.4 ± 0.4 
 
Ciprofloxacin 331 -0.3 2 6 3 226.8 6.4 ± 0.4 
 
8.7 ± 0.1 
 
Enoxacin 320 -0.6 2 7 3 230.7 6.0 ± 0.7 
 
8.2 ± 0.1 
 
Fleroxacin 321 -0.3 1 6 4 262.1 --* 
 
7.2 ± 0.4 
 
Gatifloxacin 375 -0.2 2 7 4 270.8 6.4 ± 0.5 
 
8.7 ± 0.4 
 
Gemifloxacin 389 -0.7 3 9 6 236.3 6.0 ± 0.7 
 
9.2 ± 0.3 
 
Grepafloxacin 359 0.6 2 6 3 263.0 6.4 ± 0.5 
 
8.7 ± 0.4 
 
Levofloxacin 361 -0.4 1 7 2 244.0 5.2 ± 0.4 
 
7.4 ± 0.4 
 
Lomefloxacin 351 0.04 2 6 3 261.6 --* 
 
8.6 ± 0.4 
 
Moxifloxacin 401 0.3 2 7 4 285.0 6.4 ± 0.5 
0 
10.6 ± 0.2 
 
Norfloxacin 319 -0.7 2 6 3 237.4 --* 
 
8.7 ± 0.1 
 
Ofloxacin 361 -0.4 1 7 2 244.0 5.2 ± 0.4 
 
7.4 ± 0.4 
 
Pefloxacin 333 -0.2 1 6 3 252.5 --* 
 
7.4 ± 0.4 
 
Rufloxacin 363 -0.3 1 6 2 234.9 5.2 ± 0.2 
 
7.3 ± 0.4 
 
Sparfloxacin 392 0.8 4 7 4 273.2 6.4 ± 0.5 
 
8.6 ± 0.6 
 
Temafloxacin 417 -0.9 2 6 3 292.5 6.0 ± 0.4 
 
8.7 ± 0.4 
 
Trovafloxacin 416 -1.1 3 7 4 258.3 5.8 ± 0.7 
v 
7.9 ± 0.2 
 
Prulifloxacin 462 1.1 1 9 4 283.6 5.9 ± 0.4 
 
6.3 ± 0.7 
 
 
*The software was unable to accurately predict acidic pKa values for fleroxacin, lomefloxacin, norfloxacin and pefloxacin;  
MW: molecular weight; Log D (pH = 7.4): logarithmic value for the distribution coefficient at pH 7.4; HBD: number of hydrogen 
bond donors; HBA: number of hydrogen bond acceptors; nRot: number of rotatable bonds; pKa (acidic): most acidic pKa value; pKa 
(basic): most basic pKa value. Antofloxacin was excluded in this analysis as physicochemical could not be obtained for this FQ by the 
software. (Adapted from manuscript published in Expert Opin Drug Metab Toxicol. May 2012; 8(5): 553-69) 
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Table 3.6.  Ionization profiles for fluoroquinolones in systemic (pH 7.4) and urinary (pH 
6.3) compartments 
 
 
Ionization profile (%) at pH 6.3 
 
Ionization profile (%) at pH 7.4 
 
Drug: A C N Z A C N Z 
Amifloxacin 4 59 13 23 57 5 13 25 
Ciprofloxacin  60  39 7 10  82 
Enoxacin  20  78 14   84 
Fleroxacin 30 7 3 60 86   13 
Gatifloxacin  49  51 7 7  86 
Gemifloxacin  18  82    97 
Grepafloxacin  61  39 6 10  83 
Levofloxacin 11 7  82 62   37 
Lomefloxacin  13  86 10   88 
Moxifloxacin  49  51 7   93 
Norfloxacin  17  82 8   90 
Ofloxacin 11 7  82 62   37 
Pefloxacin 9 14  75 60   39 
Prulifloxacin 55 6 23 17 95   3 
Rufloxacin 25 5  67 82   17 
Sparfloxacin  63  36 8 11  80 
Trovafloxacin 6 14  80 47   52 
Temafloxacin  41  59 7 5  88 
 
Molecular microspecies: A (anionic), C (cationic), N (neutral), and Z (zwitterionic).  Determined 
using ACD/PhysChem Suite Version 12 (Advanced Chemistry Development, Inc). 
*Antofloxacin was excluded in this analysis as physicochemical could not be obtained for this 
FQ by the software. (Adapted from manuscript published in Expert Opin Drug Metab Toxicol. 
May 2012; 8(5): 553-69) 
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CHAPTER 4 
 
HUMAN ORGANIC CATION TRANSPORTERS 1 (SLC22A1), 2 (SLC22A2), 3 
(SLC22A3) AS DISPOSITION PATHWAYS FOR FLUROQUINOLONE 
ANTIMICROBIALS 
(draft of a manuscript submitted to the journal: Antimicrobial Agents and Chemotherapy) 
 
 
 
 
4. A. INTRODUCTION 
Through decades of clinical advancement, the quinolones, now known as fluoroquinolones 
(FQ), have been widely popular as broad-spectrum antimicrobials, in human as well as 
veterinary medicine (6, 66, 141). They are utilized for infections of the soft-tissue, skin, bone, 
meninges, respiratory tract, gastrointestinal tract, and genitourinary tract (66). For example, 
ciprofloxacin and ofloxacin undergo considerable hepatobiliary elimination resulting in high 
concentrations in the feces and, hence, are preferentially indicated for treating gastrointestinal 
infections (66, 68, 96). Whereas, e.g., ciprofloxacin, levofloxacin, norfloxacin, and ofloxacin, are 
known to be renally eliminated as the ‗unchanged drug‘, resulting in urinary concentrations of 
parent drug that are much higher than their minimum inhibitory concentrations for most 
infectious bacteria, thus rendering them as important antimicrobials for genitourinary tract 
infections (9, 47). 
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The development of newer FQs has enabled improved efficacy and therapeutic duration 
of action. However, this pharmacological benefit of higher systemic and tissue concentrations 
has resulted in a number of FQs demonstrating mild to severe toxicities, eventually leading to 
withdrawal from the pharmaceutical market for some (98). Moreover, all currently marketed FQs 
have been mandated by the FDA to carry labeled warnings associated with their use, due to side 
effects like tendinitis (in 2008) and exacerbation of Myasthenia Gravis (in 2011). With the 
existence of such broad toxicities associated with the use of FQs, there is an increased need to 
elucidate the underlying biochemical mechanisms driving their overall kinetics and target organ 
disposition. Such knowledge should aid a priori identification of potential drug-drug interactions, 
as well as future drug design strategies. 
Considering that renal excretion is one of the major elimination pathways for most FQs 
after entering the systemic circulation (121, 126), investigations regarding the mechanisms 
governing their flux across renal proximal tubule cells (RPTC), i.e., renal basolateral uptake 
(removal from the blood into RPTC), apical efflux (from the RPTC into the urinary space), and 
potential reabsorption (from the urinary space back into the RPTC), are warranted. Further, as 
the basic structural scaffold of FQs has essentially remained unchanged (198), all FQs are 
predicted to exist predominantly as ionized molecules in the physiological pH range; having co-
existent cationic, anionic, and electroneutral (zwitterionic and/or neutral) species (116). Due to 
their mostly ionic nature, passive diffusion should account for a negligible component of their 
movement across cell membranes, leaving active transport and facilitated diffusion mechanisms 
likely to govern the overall kinetics of these agents in the body (116, 165). 
Recently, we conducted a systematic review of clinical literature reporting in vivo 
pharmacokinetic properties of FQs and correlated this data with available in vitro studies 
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examining FQ interactions with transporters (116, 165). This allowed identification of a subset of 
FQs (ciprofloxacin, enoxacin, fleroxacin, gatifloxacin, levofloxacin, lomefloxacin, moxifloxacin, 
norfloxacin, ofloxacin, pefloxacin, prulifloxacin, rufloxacin and sparfloxacin) with high potential 
to interact with members of the SLC22 (organic cation/anion/zwitterion transporters) family, 
which are known to be expressed in the RPTC and to mediate RPTC flux of such charged 
species (116, 165). For example, a number of clinical studies have documented significant 
changes in FQ (e.g., enoxacin, fleroxacin, and levofloxacin) pharmacokinetics upon concomitant 
administration with cimetidine, a well-characterized substrate of human (h)OCT1 (SLC22A1) 
and hOCT2 (SLC22A2), and inhibitor of hOCT3 (SLC22A3) (91, 172, 181). A significant 
decrease in the renal (CLren) and total (CLtot) clearances (each ~13-28%) of the FQs was 
observed, with an accompanying increase in the area under the concentration curve from zero 
time-point to infinity (AUC0-inf) by ~28% for enoxacin and levofloxacin (42, 111, 149). 
Similarly, co-administration of ciprofloxacin, levofloxacin, or ofloxacin with procainamide, a 
class I antiarrhythmic agent and known inhibitor of the hOCTs, significantly reduced CLren and 
increased AUC0-inf of procainamide and its metabolite, N-Acetylprocainamide (NAPA) in 
patients (10, 58, 103, 104, 110, 202). Levofloxacin induced the greatest effect, decreasing the 
CLren of procainamide by ~26% and of NAPA by ~20% (10).  
In accordance with this ‗clinical footprint‘ for hOCT involvement in renal FQ 
disposition, recent in vitro studies using stably transfected cell lines have demonstrated inhibition 
of hOCT2, a membrane potential sensitive facilitated diffusion carrier targeted to the basolateral 
membrane of RPTC, by grepafloxacin (Ki value = 10.4 µM), levofloxacin (IC50 = 127 ± 27 µM) 
and moxifloxacin (72, 91, 125). However, potential FQ interactions with hOCT1 and hOCT3 
have not been investigated. Thus, the objective of this work was to kinetically characterize the 
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potency of interaction of the identified subset of FQs with hOCT1, hOCT2 and hOCT3 and then 
apply this information to quantitatively assess the clinical relevance of any such interaction via 
calculation of the drug-drug interaction index (unbound Cmax/IC50 or Ki). 
 
4. B. MATERIALS AND METHODS 
4.B.1. Chemicals and reagents 
Unlabeled tetraethylammonium (TEA) bromide and 1-methyl-4-phenylpyridinium (MPP
+
) 
iodide were purchased from Sigma Aldrich (St. Louis, MO). Quinine monohydrochloride 
dihydrate was purchased from Fisher Scientific (Waltham, MA). Ciprofloxacin hydrochloride, 
norfloxacin and ofloxacin hydrochloride were purchased from MP Biomedicals (Solon, OH). 
Enoxacin, fleroxacin, gatifloxacin, levofloxacin hydrochloride, lomefloxacin hydrochloride, 
moxifloxacin hydrochloride, pefloxacin mesylate, prulifloxacin, rufloxacin hydrochloride, and 
sparfloxacin were purchased from LKT Laboratories, Inc. (St. Paul, MN). Radiolabeled 
[
14
C]TEA and [
3
H]MPP
+
 were obtained from PerkinElmer (Waltham, MA). Dulbecco‘s 
Modified Eagle‘s Medium with high glucose (DMEM) and Serum Supreme were purchased 
from Fisher Scientific (Waltham, MA). Penicillin/streptomycin and G418 (geneticin) were 
purchased from Invitrogen Life Technologies (Grand Island, NY) and VWR International 
(Radnor, PA), respectively. 
4.B.2. Cell line maintenance and transport assay 
The human embryonic kidney (HEK293) cell lines stably-expressing hOCT1, hOCT2, or 
hOCT3, and the corresponding empty vector transfected background control line (HEK293-EV), 
were developed as described previously (54, 55). Cell lines were maintained in DMEM 
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containing 10% Serum Supreme, 1% penicillin/streptomycin, and G418 (100 µg/ml) at 37ºC 
with 5% CO2. 
Accumulation assay protocols were adapted from our previously published methods (187, 
195). Briefly, cells were seeded in 24-well tissue culture plates (250,000 cells/well) and grown in 
the absence of antibiotics for 2 days under suitable cell culture conditions (37°C and 5% CO2). 
On the day of the experiment, the culture medium was removed and cells were equilibrated for 
10 min with transport buffer (Hank's balanced salt solution containing 10 mM HEPES, pH 7.4; 
Sigma-Aldrich, Saint Louis, MO). Next, this transport buffer was removed and replaced with 
500 μl of transport buffer containing either 1-30 μM unlabeled TEA with [14C]TEA (0.25 
μCi/ml) added as tracer for hOCT1 and hOCT2, or 1-30 μM unlabeled MPP+ with [H3]MPP+ 
(0.25 μCi/ml) added as tracer for hOCT3 in presence/absence of 0.1-2,000 μM FQs or 200 µM 
quinine (as detailed in figure legends). Following incubation, buffer was removed and the cells 
were immediately rinsed three times with excess ice-cold transport buffer, lysed in 200 μl of 1 M 
NaOH, neutralized with 250 μl of 1 M HCl plus 200 µl of 0.1 M HEPES. Aliquots were assayed 
for radioactivity by liquid scintillation counting and for total protein content using a Bradford 
protein assay kit (BioRad, Hercules, CA). Uptake was reported as picomoles per milligram total 
cell protein. All experiments were performed at least three times in triplicate (i.e., three 
wells/treatment repeated at least three times). 
4.B.3. Kinetic and statistical analyses 
All data used in kinetic determinations were corrected for background accumulation in 
HEK293-EV cells prior to analysis. Dose-response curves were analyzed by nonlinear regression 
using GraphPad Prism
®
 software version 5.04 (GraphPad, San Diego, CA). Prior to 
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determination of inhibition constants (Ki value), the Michaelis Menten constants (Km values) for 
TEA and MPP
+
 were validated with those previously published for hOCT1 and hOCT3 (91, 
102). Further, the type of inhibition was evaluated using mixed model inhibition analysis (22). 
This model uses the following equations to assess the mode of inhibition: 
                    and         
With the final equation being,              
where ‗Y‘ is the substrate (in this case TEA/MPP+) uptake rate observed, ‗X‘ and ‗I‘ are the 
substrate and inhibitor (FQ) concentrations respectively, Vmax is the maximum transporter 
velocity in absence of the inhibitor, Km value is the Michaelis-Menten constant of the substrate 
and Ki value is the inhibition constant generated from the experimental dataset. The type of 
inhibition is defined by the ‗alpha value‘ (α) obtained. Inhibition is identified as competitive, if α 
is a large number (α > 1), as non-competitive, if α = 1, or as uncompetitive, if α is small, but 
greater than zero (0 < α < 1) (22). Subsequently, Ki values for the FQs were calculated using the 
appropriate model based upon the identified inhibition mechanism. 
Data are reported as mean  S.E.M. Statistical significance was determined using one-
way analysis of variance (ANOVA) with Dunnett‘s pairwise comparison post hoc test to 
measure significant differences. The value for significance was set at 0.05. 
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4. C. RESULTS 
4.C.1. Characterization of fluoroquinolone interaction with human OCT1 
TEA uptake in HEK293-hOCT1 cells (25.41 ± 2.3 pmol/mg protein/15 min) was ~18 fold higher 
than that measured in HEK293-EV cells (1.44 ± 0.18 pmol/mg protein/15 min), which exhibited 
a consistent quinine-insensitive (data not shown) background accumulation of ~5-6% (Figure 
4.1). Addition of 200 µM quinine (vs. 1 µM TEA) reduced TEA accumulation in the HEK293-
hOCT1 cells to the background level observed in HEK293-EV cells. In order to grossly identify 
which, if any, of the FQs of interest exhibited inhibition of hOCT1 transport strong enough to 
warrant further kinetic analysis (≤ ~60% inhibition), they were each independently tested at a 
concentration of 1 mM (Figure 4.1). Under these conditions, enoxacin failed to produce 
significant inhibition of hOCT1, while ciprofloxacin (~33%), fleroxacin (~20%), levofloxacin 
(~38%), lomefloxacin (~43%), norfloxacin (~24%), ofloxacin (~38%), pefloxacin (~40%) and 
rufloxacin (~47%) exhibited significant, but weak inhibition. Only gatifloxacin (~77%), 
moxifloxacin (~85%), prulifloxacin (~75%), and sparfloxacin (~75%) produced inhibition 
greater than 60% (level of inhibition established as the cut-off value under these preliminary test 
conditions for further kinetic analysis). 
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Figure 4.1. Inhibition of human OCT1-mediated transport by fluoroquinolones 
Uptake of 1 µM [
14
C]TEA was measured for 15 min in HEK293 cells stably expressing hOCT1 
(open bar) in presence of unlabeled FQs (1 mM) or quinine (200 µM), a prototypical hOCT 
inhibitor, (black bars). The mock-vector transfected HEK293-EV cells served as a reference for 
nonspecific background substrate accumulation (grey bar). Uptake is expressed as a percentage 
of the positive control (HEK293-hOCT1). Values are expressed as mean ± S.E.M. and 
significant differences between HEK293-hOCT1 and treatments were analyzed using one-way 
ANOVA analysis followed by Dunnet‘s post hoc test (*** p<0.001). 
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To identify the proper model(s) to utilize for determination of inhibition potencies (Ki 
values) for gatifloxacin, moxifloxacin, prulifloxacin, and sparfloxacin on hOCT1, experiments 
were conducted to identify the mode of inhibition produced by each compound. Previous work 
found hOCT1-mediated TEA accumulation in HEK293 cells to be linear through at least 2 min 
and reported a Michaelis-Menten constant (Km) value of 229 µM for TEA, and we obtained 
similar results in our laboratory (55, 91). Based on these parameters we performed independent 
saturation analysis experiments using an accumulation time of 1 min and a TEA concentration of 
1 µM in the absence and presence of two concentrations of each FQ; gatifloxacin, moxifloxacin, 
and prulifloxacin each at 200 µM and 500 µM and sparfloxacin at 150 µM and 350 µM. The 
mode of inhibition was then identified by nonlinear regression analysis of background-corrected 
data using the ‗mixed-model inhibition‘ analysis in GraphPad Prism. The α values obtained were 
all much greater than 1, indicating these four FQs are competitive inhibitors of hOCT1 (Table 
4.1). 
Finally, the strength of FQ inhibition on hOCT1 was quantitated (Ki values) by 
concentration-dependency studies (Figure 4.2). Inhibition of hOCT1-mediated TEA uptake by 
increasing FQ concentrations (0.1 - 2,000 µM) was analyzed by nonlinear regression selecting 
competitive inhibition. Ki values were estimated as 250 ± 18 µM for gatifloxacin, 161 ± 19 µM 
for moxifloxacin, 136 ± 33 µM for prulifloxacin, and 94 ± 8 µM for sparfloxacin (Figure 4.2 and 
Table 4.1). 
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Figure 4.2. Determination of binding affinities (Ki values) for gatifloxacin, moxifloxacin, 
prulifloxacin and sparfloxacin on human OCT1 
One minute [
14
C]TEA (1 µM) uptake was measured in the absence or presence of 0.1-2,000 μM 
FQs in HEK293-hOCT1 cells. Uptake was corrected for non-specific background accumulation 
in HEK293-EV cells and expressed as percent of control. Data are presented as mean ± S.E.M. 
The Ki values were determined by non-linear regression selecting competitive mode in GraphPad 
Prism. All experiments were conducted at least 3 times in triplicate and the graphs are single 
representative experiments. 
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4.C.2. Characterization of fluoroquinolone interactions with human OCT2  
TEA uptake in HEK293-hOCT2 cells (136.58 ± 1.74 pmol/mg protein/15 min) was ~60 fold 
higher than that detected in HEK293-EV cells (2.24 ± 0.37 pmol/mg protein/15 min = quinine-
insensitive (data not shown) background accumulation of ~1-2%) (Figure 4.3). Addition of 200 
µM quinine (vs. 1 µM TEA) inhibited the TEA accumulation in HEK293-hOCT2 cells by ~80%. 
As described above, we first sought to identify those FQs (1 mM) capable of producing strong 
inhibition of hOCT2-mediated TEA (1 µM) uptake (Figure 4.3). In marked contrast to hOCT1, 
none of the examined FQs significantly inhibited hOCT2 under these conditions. In fact, 
enoxacin, norfloxacin, ofloxacin, pefloxacin, rufloxacin, and sparfloxacin appeared to stimulate 
TEA uptake under these conditions (Figure 4.3). In the absence of inhibition, no further kinetic 
analysis was performed. 
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Figure 4.3. Effect of fluoroquinolones on human OCT2-mediated transport 
Uptake of 1 µM [
14
C]TEA was measured for 15 min using HEK293 cells stably expressing 
hOCT2 in absence (open bar) or presence of 1 mM unlabeled FQs or 200 µM quinine (black 
bars). The mock-vector transfected HEK293-EV cells served as a reference for nonspecific 
background substrate accumulation (grey bar). Uptake is shown as percent of control (HEK293-
hOCT2). Values are given as mean ± S.E.M. and significant differences between HEK293-
hOCT2 and treatments were analyzed using one-way ANOVA analysis followed by Dunnet‘s 
post hoc test (*p<0.05, **p<0.01, and ***p<0.001). 
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4.C.3. Characterization of fluoroquinolone interactions with human OCT3  
To track hOCT3 transport activity, MPP
+
 (1 µM) was used as substrate (Figure 4.4). MPP
+
 
accumulation in HEK293-hOCT3 expressing cells (84.09 ± 4.29 pmol/mg protein/15 min) was 
~21 fold greater than that obtained in the control HEK293-EV cells (4.01 ± 0.17 pmol/mg 
protein/15 min). Accumulation of MPP
+
 in the HEK293-EV cells was insensitive to addition of 
200 µM quinine (data not shown), however accumulation in the HEK293-hOCT3 cells in the 
presence of quinine was dampened to a level similar to that measured in the control cells. Similar 
to what was observed for hOCT2, none of the FQs (1 mM), with the exception of moxifloxacin 
(~30%), inhibited hOCT3-mediated transport under test parameters (Figure 4.4). Again, apparent 
stimulation of transport activity occurred in the presence of some FQs, namely fleroxacin, 
levofloxacin, lomefloxacin, ofloxacin, and pefloxacin. Other than ofloxacin and pefloxacin each 
being associated with increased substrate uptake by hOCT2 and hOCT3, no consistent pattern of 
inhibition or stimulation was noted across transporters or substrates (Refer Appendix III). 
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Figure 4.4. Effect of fluoroquinolones on human OCT3-mediated transport  
Uptake of 1 µM [
3
H]MPP
+
 was measured for 15 min in HEK293 cells stably expressing hOCT3 
in absence (open bar) and presence of 1 mM unlabeled FQs or 200 µM quinine (black bars). The 
mock-vector transfected HEK293-EV cells served as a reference for nonspecific background 
substrate accumulation (grey bar). Uptake on was plotted as a percentage of the positive control 
(HEK293-hOCT3). Values are expressed as mean ± S.E.M. and significant differences between 
HEK293-hOCT3 and treatments were analyzed using one-way ANOVA followed by Dunnet‘s 
post hoc test (**p<0.01 and ***p<0.001). 
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Although the inhibition produced by moxifloxacin was somewhat weak, since it was the 
only FQ to produce any significant inhibition of hOCT3 and it was one the strongest inhibitors of 
hOCT1, we performed kinetic analysis of this compound on hOCT3 to allow for comparison. 
Previous work reported hOCT3-mediated MPP
+
 accumulation in HEK293 cells to be linear 
through at least 2 min with a Km value of ~40-50 µM, and we confirmed similar results in our 
laboratory (54, 91, 102). Nonlinear regression analysis (using ‗mixed-model inhibition‘) of 
background-corrected saturation data (accumulation time of 1 min with 1 µM MPP
+
) collected in 
the absence and presence of moxifloxacin at 500 µM and 1,000 µM yielded an α value much 
greater than 1, indicating competitive inhibition (Table 4.1). Subsequent dose-dependence 
experiments using 0.1 - 2,000 µM moxifloxacin to inhibit MPP
+
 uptake yielded a Ki estimate of 
1,598 ± 146 µM (Figure 4.5 and Table 4.1). 
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Figure 4.5. Determination of the binding affinity (Ki value) for moxifloxacin on human 
OCT3 
[
3
H]MPP
+ 
uptake was measured for 1 min in the absence or presence of 0.1-2,000 μM 
moxifloxacin in HEK293-hOCT3 cells. Uptake was corrected for non-specific background 
accumulation in HEK293-EV cells and expressed as percent of control. Data are presented as 
mean ± S.E.M. The Ki value was determined by non-linear regression selecting competitive 
mode in GraphPad Prism. The experiment was conducted 3 times in triplicate and the graph is a 
single representative experiment. 
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Table 4.1. Kinetic parameters, unbound Cmax, and calculated drug-drug interaction indices 
for human OCT1 and OCT3. 
Ki: inhibition constant; Unbound Cmax: unbound maximum plasma concentration obtained from 
human pharmacokinetic studies conducted in healthy adults (age: 18-45 y) after correction for 
plasma protein binding (concentrations are expressed as a range for the different doses 
administered); Drug-drug Interaction Index: calculated as unbound Cmax/Ki; IV: intravenous; ---: 
only the active metabolite of prulifloxacin, ulifloxacin, is detected in the systemic circulation. 
 α value Ki 
(µM) 
Unbound Cmax 
(µM) 
Drug-drug 
Interaction 
Index 
References 
(for unbound 
Cmax) 
hOCT1 
Gatifloxacin 1.66 х 10
11
 250 ± 18 3.54 - 12.22 
(200-800 mg  
IV dose) 
0.01-0.05 (43, 119) 
Moxifloxacin 7.16 х 10
25
 161 ± 19 3.79 - 4.06 
(400 mg IV dose) 
0.02-0.03 (156, 157) 
Prulifloxacin 2.62 х 10
20
 136 ± 33 ---   
Sparfloxacin 6.88 х 10
22
 94 ± 8 1.81 - 2.79 
(200-800 mg  
oral dose) 
0.02-0.03 (112, 113) 
hOCT3 
Moxifloxacin 9.27 х 10
16
 1,598 ± 
146 
3.79 - 4.06 
(400 mg IV dose) 
0.002-0.003 (156, 157) 
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4. D. DISCUSSION 
Fluoroquinolones are one of the most commonly prescribed and efficacious antimicrobials 
for many infections. However, many of the newer broad-spectrum FQs are often not used as 
primary therapeutics purportedly due to cost-effectiveness, concern about development of 
bacterial resistance, risk to special populations, and a variety of mild-to-severe toxicities 
observed in many patients (47, 70, 129, 206). Clearer understanding of the biochemical pathways 
governing their kinetics in the body, drug interactions, and associated organ toxicities should aid 
development of clinical strategies to circumvent these issues, as well as support discovery of 
more efficacious FQs. As the clinical pharmacokinetics of FQs are known to be affected by 
identified renal organic cation transport system inhibitors and substrates, and FQs are 
predominantly zwitterionic in nature in the gastrointestinal environment and the systemic 
circulation, they have been explored for potential interactions with organic cation/zwitterion 
transport systems (116). Within the Amphiphilic Solute Carrier (SLC) superfamily, members of 
the SLC22 (organic cation/anion/zwitterion transporters) and SLC47 (multidrug and toxin 
extrusion transporters) families are known to transport organic cations, and have been 
preliminarily examined with respect to FQ interaction (Figure 4.6). Inhibition of hOCT2 
(SLC22A2), hOCTN1 (SLC22A4), and hOCTN2 (SLC22A5) by both levofloxacin and 
grepafloxacin has been observed (62, 72, 125, 204). Ciprofloxacin and levofloxacin were 
reported to inhibit hMATE1 (SLC47A1) and hMATE2K (SLC47A2), with IC50 values of 
231 ± 57.3 μM and 38.2 ± 11.8 μM, respectively, for hMATE1, and 98.7 ± 14.1 μM and 
81.7 ± 23.1 μM, respectively, for hMATE2K (175). Thus, members of these transporter families 
may be important determinants of FQ disposition in vivo. 
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Human OCT1 (SLC22A1), hOCT2, and hOCT3 (SLC22A3) are facilitated diffusion 
carriers that mediate cellular uptake of substrates (91, 165). Human OCTN1 and hOCTN2 are 
antiporters, with hOCTN1 mediating H
+
/organic cation or organic cation/organic cation 
exchange, whereas hOCTN2 has been linked to carnitine uptake via carnitine/organic cation 
exchange as well as organic cation/organic cation exchange (91, 165). Thus, they can mediate 
cellular entry or exit, depending upon membrane localization and substrate gradients. In the 
enterocyte (Figure 4.6), hOCT3, hOCTN1, and hOCTN2 are expressed in the apical/luminal 
membrane and may mediate FQ absorption (91, 165). hOCT1 and hOCT2 are also found in 
enterocytes, however, they are localized to the basolateral membrane and would therefore 
mediate FQ uptake from the systemic circulation into the enterocyte. In hepatocytes (Figure 4.6), 
hOCT1 and hOCT3 are known to be expressed in the basolateral/sinusoidal membrane and may 
influence hepatic FQ influx (91, 165). Finally, in the RPTC (Figure 4.6), hOCT2 and hOCT3 are 
basolateral and may participate in FQ accumulation from the blood, whereas, hOCTN1 and 
hOCTN2 are targeted to the apical/brush border membrane and represent potential FQ efflux 
and/or reabsorptive pathways (91, 165). Renal expression and targeting of hOCT1 remains 
controversial, with conflicting localization reports in the literature, however, the rat Oct1 
ortholog has been immunolocalized to the basolateral membrane of RPTCs (80). For the SLC47 
family, the transporter hMATE1 (SLC47A1) has been localized to the apical membrane of 
hepatocytes and RPTCs, and hMATE2K (SLC47A2) is targeted to the apical membrane of 
RPTCs, with potential roles in FQ entry into bile and/or urine (16, 91, 92, 127). Thus, a number 
of transporters belonging to the SLC superfamily are known to be expressed in the intestine, 
liver, and kidney and are poised to contribute to the absorption, distribution, and excretion of FQ 
antimicrobials. 
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Figure 4.6. Models depicting membrane targeting of transporters discussed in this study in 
enterocytes, hepatocytes, and renal proximal tubule cells 
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The results reported herein suggest that, at least for the examined set of 13 FQs, only hOCT1, 
and not hOCT2 or hOCT3, is likely to be involved in FQ disposition (Figures 4.1, 4.3 and 4.4). 
Thus, although there is high amino acid sequence homology between hOCT1, hOCT2, and 
hOCT3 (~50-70%), there is a stark difference between FQ specificity of these transporter 
paralogs (3, 165). The mode of inhibition and concentration-dependency experiments enabled 
calculation of inhibition constants (Ki values) for hOCT1, which indicated potential for FQ 
inhibition of this transporter‘s activity with a rough potency hierarchy of sparfloxacin ≥ 
prulifloxacin ≅ moxifloxacin ≥ gatifloxacin (Table 4.1). Human OCT1 expression in the 
basolateral membranes of enterocytes, hepatocytes, and perhaps RPTC, indicates hOCT1-
mediated accumulation from the systemic circulation may play a role in the disposition of these 
FQs (Figure 4.6 and Table 4.1). Moxifloxacin was found to be a relatively weak inhibitor of 
hOCT3 with a Ki value of ~1,600 µM. However, given a high luminal GI tract concentration of 
moxifloxacin after oral dosing, hOCT3 may represent an important pathway for moxifloxacin 
absorption due to its localization in the apical membrane of enterocytes and facilitated diffusion 
mechanism of action. Further, hepatic metabolism accounts for ~80% of moxifloxacin 
elimination (91, 145), and abundant hepatocyte expression of hOCT1 in the sinusoidal 
membrane combined with the modest Ki value of 161 µM, may indicate a role for hOCT1 in the 
hepatic uptake of moxifloxacin from the systemic circulation, facilitating the metabolism and 
elimination of this FQ. Also, in case of the prodrug prulifloxacin, a similar Ki value of 136 µM 
for hOCT1 coupled with high pre-systemic concentrations (following GI absorption, >> Ki value 
for hOCT1), may suggest an important role of this OCT in mediating the first-pass metabolism 
of this prodrug FQ to its active metabolite (ulifloxacin) (See Chapter 3, Section 3.C.) (12, 81). 
Lack of interaction of prulifloxacin with hOCT3, suggests that the GI absorption of this prodrug 
  
61 
 
may not be mediated by this transporter (Figure 4.4); on the other hand, hOCT1 may potentially 
be involved in the uptake of prulifloxacin from the blood back into the enterocyte thus slowing 
down its hepatic metabolism and resultant conversion to its active FQ (Figure 6, See Chapter 3, 
Section 3.C). Nevertheless, these postulations are based on the assumption that the aforesaid FQs 
are not only inhibitors for the OCTs, but are also being transported by these OCTs (substrates). 
The complete lack of interaction of levofloxacin with hOCT2 (Figure 4.3) is in discrepancy with 
a previously published study which found a relatively potent inhibition (IC50 for hOCT2 = 127 ± 
27 µM) (125). However, the substrate used in the published study was creatinine, which has a 
~9-10 fold lower affinity for hOCT2 as compared to TEA (Km for creatinine = 4,000 µM vs. Km 
for TEA = 431 ± 87 µM), and the laboratory settings as well as the experimental design were 
different (182, 183). Moreover, the results obtained herein concur with another study that found 
no effect of 2.5 mM levofloxacin on hOCT2-mediated transport (182). 
Recently, a quantitative method to assess the potential clinical relevance of such 
transporter interactions, based on the kinetic parameters obtained through in vitro assays, 
referred to as the drug-drug interaction index (DDI index), has been suggested 
(http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/u
cm292362.pdf) (73). The DDI index is defined as the ratio of the unbound maximal plasma 
concentration (unbound Cmax) of the drug divided by the in vitro Ki or IC50 value determined for 
a particular transporter. A value ≥ 0.1 indicates potential for clinically relevant DDIs in instances 
of co-administration/poly-pharmacy with other drugs identified as inhibitors or substrates of the 
transporter in question. The implication for the pharmaceutical industry being that in vivo drug 
interaction studies would have to be conducted prior to obtaining FDA approval 
(http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/u
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cm292362.pdf). Consequently, we compiled human in vivo pharmacokinetic and protein binding 
studies for gatifloxacin, moxifloxacin, prulifloxacin, and sparfloxacin, and calculated DDI 
indices for hOCT1 and hOCT3 (Table 4.1). As indicated, all DDI index values were found to be 
< 0.1 over prescribed dosing ranges, suggesting these interactions have low potential to result in 
clinically relevant DDIs on hOCT1 or hOCT3. However, such individual transporter interactions 
could be of considerable importance in situations where FQs would be ideally prescribed, e.g., in 
acute exacerbation of chronic bronchitis, in patients with complicated urinary tract infections 
(UTI), or trimethoprim-sulfamethoxazole resistance during the treatment of UTIs (47, 66). In 
addition to such scenarios, FQ based interactions may gain importance where there exists an 
inter-patient variability associated with enzymatic and/or transporter-based single nucleotide 
polymorphisms (SNPs), affecting the kinetics and resultant pharmacodynamics of the interacting 
drugs (10, 83, 108). For example, the levofloxacin-cimetidine interaction was suggested to be 
clinically important in patients who were ‗slow acetylators‘ (acetylation being an important 
metabolic step in procainamide elimination), as renal elimination would become the primary 
excretion pathway for procainamide in such a scenario (10). 
Unexpectedly, some FQs produced significant stimulation of hOCT-mediated TEA/MPP
+ 
uptake (Figures 4.3 and 4.4). However, this effect varied considerably among the hOCTs for 
individual FQs with no readily identifiable pattern or association with FQ structural features. For 
example, ofloxacin and pefloxacin significantly inhibited hOCT1, yet significantly stimulated 
hOCT2- and hOCT3-mediated uptake (Figures 4.1, 4.3 and 4.4). In contrast, ciprofloxacin, 
gatifloxacin, and prulifloxacin each inhibited hOCT1, but were without effect on hOCT2 or 
hOCT3. Further, norfloxacin, rufloxacin, and sparfloxacin inhibited hOCT1, stimulated hOCT2 
activity, but were without effect on hOCT3 activity; while fleroxacin, levofloxacin, and 
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lomefloxacin inhibited hOCT1, were without effect on hOCT2 activity, but stimulated hOCT3. 
Such sporadic transporter stimulation/inhibition by FQs has been previously reported in the 
literature, e.g., ciprofloxacin caused stimulation of hOAT1, but inhibition of hOAT3 (187) and 
sparfloxacin was described as a ‗borderline stimulator‘ for MRP2 (130). In fact, such in vitro 
stimulation of transporter activity actually has been observed for a variety of drug classes in 
addition to FQs, including steroids, anticancer chemotherapeutics, and non-steroidal anti-
inflammatory drugs (87, 130, 187). It was postulated that such effects are due to interaction with 
an allosteric binding site(s), causing a conformational change to the transport protein and 
consequently modulating the kinetics of substrate molecules (87, 130). The stimulatory behavior 
by some FQs observed herein for hOCT2 and hOCT3 is consistent with such an allosteric 
binding mechanism. However, considering the varied response among the hOCTs (Figures 4.1, 
4.3, and 4.4), the fact that several of these FQs were demonstrated to be competitive inhibitors of 
hOCT1 (Table 4.1), the high degree of sequence homology between hOCT1-3 (50-70%), and 
their similar predicted membrane topologies, the location and make-up of such unique allosteric 
binding sites remains unclear and requires much further investigation. 
Finally, whether such stimulatory effects of FQs on hOCTs are observed in vivo is an 
important novel question. In contrast to inhibitory DDIs, where victim drug pharmacokinetics are 
characterized by decreased elimination and increased terminal half-life, such stimulatory DDIs 
could result in increased elimination and shortened terminal half-life of victim drugs resulting in 
marked loss of efficacy. For example, hOCT2 has recently been identified as a key mediator in 
renal elimination of metformin, an important therapeutic in the treatment of type 2 diabetes (86, 
109, 180).  Thus, concomitant use of, e.g., ofloxacin, pefloxacin, or sparfloxacin, might stimulate 
renal metformin elimination mediated by hOCT2, potentially reducing metformin‘s efficacy and 
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duration of action. If so, in situations where FQ therapy might be called for in a diabetic patient 
on metformin therapy, use of ciprofloxacin might be a more prudent clinical strategy. Future in 
vitro studies aimed at unraveling the mechanistic basis of such stimulatory effects of FQs on 
hOCTs, and clinical studies designed to assess the potential impact of such effects in vivo, will 
be important next steps. 
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CHAPTER 5 
 
 
EVALUATION OF ORGANIC ANION TRANSPORTERS 1 (SLC22A6), 3 (SLC22A8), 
AND 4 (SLC22A11) AS POTENTIAL RENAL ELIMINATION PATHWAYS FOR 
FLUOROQUINOLONE ANTIMICROBIALS 
 
 
 
 
5. A. INTRODUCTION 
Amongst the large array of antibacterial agents used in human and veterinary medicine, 
FQs continue to be prescribed as potent broad-spectrum antibiotics (6, 66, 126). The 
development of newer FQs has resulted in agents with wider systemic distribution 
characteristics, longer durations of action and a resultant improvement in therapeutic efficacies 
(116, 126, 159). Subsequently, FQs have been indicated for treatment of aerobic as well as 
anaerobic bacterial infections, with therapeutic applications being governed by their in vivo 
pharmacokinetics (PK) and tissue/fluid concentrations (66, 126). The newer FQs like 
gemifloxacin and moxifloxacin, achieve higher concentrations in the respiratory tract tissues and 
fluids, and hence are primarily indicated for treatment of infections like acute exacerbation of 
chronic bronchitis, community acquired pneumonia and sinusitis (66, 88). While some of the 
earlier FQ molecules like ciprofloxacin, levofloxacin, norfloxacin, and ofloxacin are known to be 
excreted primarily as the unchanged drug in urine, with concentrations much higher than their 
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minimum inhibitory concentrations for most pathogens; this has enabled their use in the 
treatment of urinary tract infections (9, 47). However, owing to increasing concern associated 
with development of bacterial resistance, special populations (pregnant women, geriatrics, 
pediatrics), and variety of observed adverse events during therapy, FQs therapy has been limited 
for most indications (47, 70, 129, 206).  
With the development of newer FQs, there have been occurrences of mild-to-severe 
adverse events associated with their use, e.g., convulsions and anxiety, torsades de pointes, 
phototoxicity, tendinitis, hypoglycemia etc. (98). Such adverse events have eventually resulted in 
withdrawal of many FQs from the worldwide pharmaceutical market (116). The existence of 
such varied toxic events has made it essential to identify the biochemical mediators which would 
govern the overall in vivo kinetics of FQs, and furthermore, aid in designing more efficient tools 
in antimicrobial therapy.  
FQs are small molecular weight (~400 Da) compounds, which predominantly exist as 
charged, i.e., coexisting cationic, anionic, and zwitterionic species, throughout the physiological 
pH range (116, 198). Due to this, it is more likely that in vivo PK of the FQs would be primarily 
driven by active transport and facilitated diffusion mechanisms, while passive diffusion would 
account for only a negligible component in their movement across membrane barriers (116, 165). 
Earlier studies have demonstrated that FQs are well absorbed systemically following oral 
administration, with moderate to excellent bioavailability (126). Subsequently, for most 
systemically absorbed FQs, renal excretion is one of the primary pathways, along with hepatic 
metabolism and minor biliary excretion (4, 116, 126). Although specific transport and metabolic 
pathways mediating the nonrenal (hepatic metabolism and biliary excretion) elimination of FQs 
have been identified, more studies have to be conducted to elucidate detailed mechanisms 
  
67 
 
governing overall renal flux of these agents across the renal proximal tubule cells (RPTC) (4, 5, 
26, 128). This would include basolateral uptake (from the circulation into RPTC), apical efflux 
(from the RPTC into the urinary space) and/or potential reabsorption (from the urinary space 
back into the RPTC), before being eliminated into the urine (4, 5, 26, 128). In fact, such 
processes (net renal tubular secretion/reabsorption) have been predicted to occur for an identified 
subset of FQs like ciprofloxacin, enoxacin, fleroxacin, gatifloxacin, levofloxacin, lomefloxacin, 
moxifloxacin, norfloxacin, ofloxacin, pefloxacin, prulifloxacin, rufloxacin and sparfloxacin, 
based on a systematic review of their clinical PK literature conducted in healthy humans (116). 
Furthermore, existence of charged species of the FQs at physiological pH has suggested the 
potential for their transport by members of the Solute Carrier (SLC) family, which mediate 
transport of charged (anionic/cationic/zwitterionic) species and are known to be expressed in the 
RPTC (116, 165). 
Early drug interaction studies conducted in humans have suggested involvement of 
organic anion transporters (OATs: SLC22 family) in renal elimination of FQs (anionic species), 
on concomitant administration of drugs like probenecid and furosemide (38, 42, 59, 75, 78, 95, 
119, 142, 144, 149, 162, 197). These studies demonstrated a significant decrease in renal 
clearance (CLren) (by ~25-60%) and in most cases, an increase in the terminal half-life and area 
under the concentration curve from zero to infinity (AUC∞) for ciprofloxacin, enoxacin, 
fleroxacin, gatifloxacin, gemifloxacin, levofloxacin, and norfloxacin, in presence of probenecid, 
a uricosuric agent and known inhibitor of OATs (38, 42, 75, 95, 119, 142, 144, 149, 197). 
However, co-administration of probenecid did not affect the kinetics of sparfloxacin and 
moxifloxacin, for which CLren of the ‗parent drug‘ accounts for a small fraction in their overall 
clearance (high hepatic metabolism) (143, 157). For lomefloxacin and furosemide (a loop 
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diuretic known to be transported by OATs) interaction, yet again, the CLren was found to 
decrease by ~33%, with ~12% increase in AUC0-12h (59, 162).  
These clinical findings have been further characterized by in vitro experiments using stably 
transfected cell lines expressing these transporters (116, 187). While earlier literature, as well as 
our study (See Chapter 4) has demonstrated in vitro evidence for FQ handling by organic 
cation/zwitterion transporter members (OCTs, OCTNs, MATEs) of the SLC superfamily, the 
role of OATs in renal disposition of these antimicrobials is still relatively uninvestigated (116). 
A recent study using stably transfected cell lines demonstrated ciprofloxacin to be a substrate for 
mouse (m)Oat3 [Michaelis Menten constant (Km) value = 70 ± 6 µM], and not mOat1 (187). 
Moreover, knockout mice experiments using clinically relevant concentrations of ciprofloxacin 
showed that the deletion of mOat3 resulted in in vivo kinetics mimicking those seen on co-
administration of probenecid with FQs in humans (187). Furthermore, concentration-dependent 
studies using cell lines have demonstrated norfloxacin, ofloxacin, and gatifloxacin to be 
moderate inhibitors of mOat3 with inhibition constants (Ki) of 558 ± 75 µM, 745 ± 165 µM, and 
941 ± 232 µM, respectively (187). For hOATs, only ciprofloxacin and gatifloxacin exhibited 
moderate inhibition of hOAT3-mediated ES uptake, but no additional characterization has been 
conducted for these FQ interactions. Thus, the objective of this work was to identify and 
characterize the potency of interactions of a selected subset of FQs with mOat1, hOAT1, mOat3, 
hOAT3 and hOAT4; and to further quantitatively assess the impact of OATs on clinically 
relevant FQ-drug interactions.  
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5. B. MATERIALS AND METHODS 
5.B.1 Chemicals and reagents 
Unlabeled paraaminohippuric acid (PAH) and estrone-3-sulfate (ES) and probenecid were 
purchased from Sigma Aldrich (St. Louis, MO). Ciprofloxacin hydrochloride, norfloxacin and 
ofloxacin hydrochloride were purchased from MP Biomedicals (Solon, OH). Enoxacin, 
fleroxacin, gatifloxacin, levofloxacin hydrochloride, lomefloxacin hydrochloride, moxifloxacin 
hydrochloride, pefloxacin mesylate, prulifloxacin, rufloxacin hydrochloride, and sparfloxacin 
were purchased from LKT Laboratories, Inc. (St. Paul, MN). Radiolabeled [
3
H]PAH and [
3
H]ES 
were obtained from PerkinElmer (Waltham, MA). Dulbecco‘s Modified Eagle‘s Medium 
(DMEM)/F12 (1:1), DMEM with high glucose and Serum Supreme were purchased from Fisher 
Scientific (Waltham, MA). Eagle‘s minimum essential medium alpha modification (EMEM) was 
purchased from Sigma Aldrich (St. Louis, MO). Penicillin/streptomycin and hygromycin B were 
purchased from Invitrogen Life Technologies (Grand Island, NY). G418 (geneticin) was 
purchased from VWR International (Radnor, PA). 
5.B.2 Cell line maintenance and transport assay.   
The human embryonic kidney 293 (HEK293) Flp-In and chinese hamster ovary (CHO) Flp-
In cell lines stably-expressing hOAT3 and mOat1 respectively, along with the corresponding 
empty vector transfected background control line (HEK293-EV and CHO Flp-In-EV 
respectively) were developed as described previously (189). The CHO cell lines stably-
expressing hOAT1 along with the corresponding empty vector transfected background control 
lines (CHO-EV), were developed as described previously (63). The CHO Flp-In cell lines stably-
expressing mOat3 along with the corresponding empty vector transfected background control 
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lines (CHO Flp-In-EV) were developed as described previously (188). The CHO-pro5 cell lines 
stably-expressing hOAT4 along with the corresponding empty vector transfected background 
control lines (CHOpro5-EV), were developed as described previously hOAT4 (207). The CHO 
Flp-In and CHO cell lines were maintained in DMEM/F12 containing 10% Serum Supreme, and 
1% penicillin/streptomycin, with hygromycin (125 µg/ml) and G418 (500 µg/ml) as the selection 
antibiotics, respectively. The HEK293 Flp-In cell lines were maintained in DMEM with high 
glucose containing 10% Serum Supreme, 1% penicillin/streptomycin and hygromycin (50 
µg/ml). The CHO-pro5 cell lines were maintained in EMEM containing 10% Serum Supreme, 
1% penicillin/streptomycin and G418 (500 µg/ml). All the cell lines were cultured at 37ºC with 
5% CO2. 
Accumulation assay protocols were adapted from our previously published methods (187, 
195). Briefly, cells were seeded in 24-well tissue culture plates (250,000 cells/well) and grown 
without antibiotics for 2 days under suitable cell culture conditions (37°C and 5% CO2). On the 
day of the transport study, culture medium was removed and cells were equilibrated for 10 min 
with transport buffer (Hank's balanced salt solution containing 10 mM HEPES, pH 7.4; Sigma-
Aldrich, Saint Louis, MO). The transport buffer was then removed and replaced with 500 μl of 
transport buffer containing either 1-30 μM ES with [3H]ES (0.25 μCi/ml) added in trace amounts 
for mOat3, hOAT3 and hOAT4, or 1-30 μM PAH with [H3]PAH (0.25 μCi/ml) added in trace 
amounts for mOat1 and hOAT1, depending on the experiment, in presence/absence of 0.1-2,000 
μM FQs or 1 mM probenecid (as detailed in figure legends). Following incubation for 1 or 15 
min (as detailed in figure legends), the buffer was removed and the cells were instantly rinsed 
three times with excess ice-cold transport buffer. This was followed by lysis in 200 μl of 1 M 
NaOH, neutralization with 250 μl of 1 M HCl plus 200 µl of 0.1 M HEPES. The aliquots were 
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then assayed for radioactivity by liquid scintillation counting, and cellular accumulation was 
normalized for total protein content using a Bradford protein assay kit (BioRad, Hercules, CA). 
Uptake was reported as picomoles per milligram total cell protein. All experiments were 
performed at least three times in triplicate (i.e., three wells/treatment repeated at least three 
times). 
5.B.3 Kinetic and statistical analyses  
Prior to analysis, all data used in kinetic determinations were corrected for background 
accumulation in the corresponding empty vector control cells for each transporter-expressing cell 
line. The inhibition dose-response curves were analyzed by nonlinear regression using GraphPad 
Prism
®
 software version 5.04 (GraphPad, San Diego, CA).  
For the kinetic studies to determine the half maximal inhibition concentration for the FQs 
(IC50), type of inhibition, and Ki values, the accumulation time of 1 min and substrate 
concentrations for ES and PAH (1-30 µM) were chosen based on previously determined 
Michaelis-Menten constant values in the cell lines: Km value for ES in mOat3 = 12.2 ± 4.8 µM 
and the Km value for PAH in hOAT1 = 15.4 µM (63, 187). Further, for the determination of Ki 
values, the type of inhibition was assessed using mixed model inhibition analysis as described 
previously (See Chapter 4; 22). The type/mode of inhibition was defined by the ‗alpha value‘ (α) 
obtained. Inhibition is identified as competitive, if α is a large number (α > 1), as non-
competitive, if α = 1, or as uncompetitive, if α is small, but greater than zero (0 < α < 1) (See 
Chapter 4; 22). Subsequently, Ki values for the FQs were calculated using the appropriate model 
based upon the identified inhibition mechanism. 
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Data are reported as mean  S.E.M. Statistical significance was determined using one-way 
analysis of variance (ANOVA) with Dunnett‘s pairwise comparison post hoc test to measure 
significant differences. The value for significance was set at 0.05. 
5. C. RESULTS 
5. C. 1. Interactions of fluoroquinolones with mouse Oat3  
The ES uptake in CHO-mOat3 cells (46.3 ± 4.9 pmol/mg protein/15 min) was ~15 fold higher 
than that detected in CHO Flp-In-EV cells (3.1 ± 0.8 pmol/mg protein/15 min; Figure 5.1), 
demonstrating a consistent probenecid-insensitive (data not shown) background accumulation of 
~6%. In presence of 1 mM probenecid (vs. 1 µM ES) the ES accumulation in CHO-mOat3 cells 
was reduced to the background level as observed in CHO Flp-In-EV cells. The FQs were tested 
independently for interaction with mOat3 at the high concentrations of 1 mM, wherein all of 
them exhibited a significant inhibition of mOat3 mediated uptake (Figure 5.1), while they 
showed a similar degree of uptake in the CHO Flp-In-EV cells (data not shown). Thus, the CHO 
Flp-In-EV cells represent a valid background correction method for the experiments. In order to 
characterize the individual inhibition potencies of the FQs for mOat3, only those FQs identified 
to produce strong inhibition (≥ 50%) of mOat3 mediated uptake were considered for further 
kinetic analysis. The FQs producing ≥ 50% inhibition were ciprofloxacin (~54%), enoxacin 
(~53%), fleroxacin (~70%), gatifloxacin (~70%), levofloxacin (~70%), lomefloxacin (~70%), 
moxifloxacin (~93%), ofloxacin (~50%), prulifloxacin (~85%) and sparfloxacin (~80%). 
Relatively weak (< 50%), but significant inhibition was exhibited by norfloxacin (~40%), 
pefloxacin (~44%) and rufloxacin (~44%). Previous kinetic studies have already characterized 
the Ki values of ciprofloxacin, gatifloxacin, norfloxacin and ofloxacin for mOat3 (187). 
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Figure 5.1. Inhibition of mouse Oat3-mediated transport by fluoroquinolones 
Uptake of 1 µM [
3
H]ES was measured at room temperature for 15 min using CHO Flp-In 
cells stably expressing mOat3 in presence of 1 mM unlabeled FQs (black bars). The inhibition by 
probenecid (1 mM), a prototypical inhibitor of OATs, was utilized in the experiments as negative 
control (black bar). The mock-vector transfected CHO Flp-In-EV cells served as a reference for 
nonspecific background substrate accumulation (grey bar).  Uptake on the X-axis is expressed as 
a percentage of the positive control (open bar).  Values are expressed as means ± S.E.M. and the 
significant differences are analyzed between the positive control treatment (with no inhibitor) 
and treatments in presence of FQs and probenecid, using one-way ANOVA statistical analysis 
followed by Dunnet‘s post hoc test in GraphPad Prism® version 5.04 (*p<0.05, **p<0.01, 
***p<0.001). All the experiments are conducted at least 3 times performed in triplicate and the 
graphs are single representative experiments. 
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Further experiments were conducted to identify the type of inhibition for mOat3 by the FQs, 
enoxacin, fleroxacin, levofloxacin, lomefloxacin, moxifloxacin, prulifloxacin and sparfloxacin, 
in order to identify the appropriate model for the determination of Ki values. Previously mOat3-
mediated ES accumulation was found to be linear through at least 5 min with Km value of 12.2 ± 
4.8 µM, and similar results were replicated in our laboratory (187). Thereafter, the saturation 
analysis was performed in the absence and the presence of two concentrations of the FQs: 200 
and 450 µM enoxacin, 400 and 750 µM fleroxacin, 500 and 1000 µM levofloxacin, 350 and 750 
µM lomefloxacin, 500 and 1000 µM moxifloxacin, 350 and 750 µM prulifloxacin, 250 and 500 
µM sparfloxacin, using 1 min as accumulation time and ES concentration of 1 µM. Nonlinear 
regression analysis was then conducted with background corrected data, and the type of 
inhibition was identified for each FQ by using the ‗mixed-model inhibition‘ analysis in 
GraphPad Prism. The resultant α values obtained were all much greater than 1, indicating these 
seven FQs are competitive inhibitors of mOat3 (Table 5.1). 
Finally, concentration-dependency studies were conducted to quantify the strength of 
inhibition of each FQ for mOat3 by determining the Ki values (Figure 5.2, Table 5.1). The 
inhibition of mOat3-mediated ES uptake was analyzed in the presence of increasing FQ 
concentrations (0.1 - 2,000 µM) and Ki values were determined by nonlinear regression, 
selecting the competitive model for inhibition. The Ki values for the different FQs were 
estimated as follows: 396 ± 14.6 µM for enoxacin, 817 ± 31.3 µM for fleroxacin, 515 ± 22.2 µM 
for levofloxacin, 539 ± 27.1 µM for lomefloxacin, 1356 ± 114 µM for moxifloxacin, 299 ± 35 
µM for prulifloxacin and 206 ± 11.6 µM for sparfloxacin (Figure 5.2 and Table 5.1). 
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Figure 5.2. Determination of binding affinities (Ki) for enoxacin, fleroxacin, levofloxacin, 
lomefloxacin, moxifloxacin, prulifloxacin and sparfloxacin on mouse Oat3   
 
[
3
H]ES uptake was measured for 1 min at 0 - 2000 μM for each FQ in CHO-mOat3 cells; Uptake 
on the Y axis is expressed as a % of the positive control (in absence of inhibitor, normalized to 
100%) and all points on the curves are expressed as means ± S.E.M. The % inhibitions for all the 
tested FQs were calculated after correcting for nonspecific accumulation in the empty-vector 
transfected cells, i.e., in CHO Flp-In-EV cells.  The type of inhibition was identified using 
‗mixed model inhibition‘ in GraphPad Prism® version 5.04 and Ki values were determined from 
non-linear regression (inhibition curves) model using competitive inhibition. The Km value for 
[
3H]ES ~12.2 μM in CHO-mOat3 cells was verified with earlier published literature (data not 
shown), and was subsequently used to calculate Ki values for the tested FQs. All the experiments 
are conducted at least 3 times performed in triplicate and the graphs are single representative 
experiments.    
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Table 5.1. Kinetic parameters, unbound Cmax, and calculated drug-drug interaction indices 
for mouse Oat3 
 
a
: Values are published results in (187); 
b
: As only the metabolite levels are detected 
systemically, the studies have not been included; 
c
: In vivo studies in mice could not be obtained 
for these FQs; α value: A constant value obtained using ‗mixed model inhibition‘ analysis in 
GraphPad Prism; Ki value: Inhibition constant expressed as Mean ± SEM; Unbound Cmax: 
Unbound maximum plasma concentration obtained from preclinical pharmacokinetic studies in 
mice, after correction for plasma protein binding.  Drug-drug Interaction Index: calculated as 
unbound Cmax/IC50 or Ki. 
  
 α value Ki 
(µM) 
Unbound Cmax 
(µM) 
Drug-drug 
Interaction 
Index 
References 
(unbound 
Cmax) 
Ciprofloxacin  198 ± 39
a
 7.3 - 9.6 
(0.1 – 0.2 mg IV) 
0.04 – 0.05 (187) 
Norfloxacin  558 ± 75
a
 0.94 
(1.3-1.6 mg oral) 
0.002 (117) 
Fleroxacin 1.6  х 10
17
 817 ± 31 ---
c 
  
Levofloxacin
 5.3  х 1017 515 ± 22 ---c   
Lomefloxacin
 4.6  х 1013 539 ± 27 ---c   
Enoxacin 1.1  х 10
19
 396 ± 15 4.98 
(1.3-1.6 mg oral) 
0.013 (117) 
Moxifloxacin 9.6 х 10
17
 1356 ± 114 2.24 
(0.27 mg oral) 
0.002 (145) 
Prulifloxacin 1.0  х 10
21
 299 ± 35 ---
b 
  
Sparfloxacin 1.5  х 10
13
 205 ± 12 0.35 
(0.15 mg oral) 
0.002 (118) 
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5. C. 2. Interactions of fluoroquinolones with human OAT3  
The ES uptake in HEK293 Flp-In-hOAT3 cells (7.94 ± 0.24 pmol/mg protein/15 min) was 
~4.8 fold higher than that detected in HEK293 Flp-In-EV cells (1.64 ± 0.16 pmol/mg protein/15 
min, probenecid-insensitive (data not shown) background accumulation of ~20%) (Figure 5.3). 
In presence of 1 mM probenecid (vs. 1 µM ES) the ES accumulation was inhibited in HEK293-
hOAT3 cells by ~70%. As described above, the FQs were initially tested at the high 
concentration of 1 mM to identify those capable of producing strong inhibition of hOAT3-
mediated ES (1 µM) uptake (Figure 5.3). At the test concentrations, the FQs demonstrated the 
same effect (negligible transport) on the HEK293 Flp-In-EV cells (data not shown); thus these 
cells represent valid background controls for these experiments. Ciprofloxacin was the only FQ 
which significantly inhibited ES uptake mediated by mOat3 as well as hOAT3 (by ~40%), while 
enoxacin, levofloxacin, moxifloxacin and prulifloxacin caused stimulation of ES uptake under 
the experimental conditions (Figure 5.3). Due to absence of any strong significant inhibition (≥ 
50%, as discussed above) of hOAT3-mediated ES uptake in presence of the FQs, no further 
kinetic analysis was performed. 
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Figure 5.3. Interactions of fluoroquinolones with human OAT3   
Uptake of 1 µM [
3
H]ES was measured at room temperature for 15 min using HEK293 Flp-In 
cells stably expressing hOAT3 in presence of 1 mM unlabeled FQs (black bars).  Probenecid (1 
mM), a prototypical inhibitor of OATs, was used for the experiments as negative control (black 
bar). The empty-vector transfected HEK293 Flp-In-EV cells served as a reference for 
nonspecific background substrate accumulation (grey bar). Uptake on the X-axis is expressed as 
a percentage of the positive control (open bar).  Values are expressed as means ± S.E.M. and the 
significant differences were analyzed between the positive control treatment (with no inhibitor) 
and treatments in presence of FQs and probenecid, using one-way ANOVA statistical analysis 
followed by Dunnet‘s post hoc test in GraphPad Prism® version 5.04 (*p<0.05, **p<0.01, 
***p<0.001).  All the experiments are conducted at least 3 times performed in triplicate and the 
graphs are single representative experiments. 
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5. C. 3. Interactions of fluoroquinolones with mouse Oat1 
To study the mOat1 transporter interaction, PAH (1 µM) was used as the prototypical 
substrate (Figure 5.4). The accumulation of PAH in the CHO Flp-In mOat1 expressing cells 
(35.5 ± 5.11 pmol/mg protein/15 min) was ~21 fold greater than that obtained in the control 
CHO Flp-In-EV cells (2.2 ± 0.3 pmol/mg protein/15 min). This PAH accumulation in the CHO 
Flp-In-EV cells was found to be insensitive to the addition of 1 mM of probenecid (data not 
shown), however accumulation in the CHO Flp-In mOat1 cells in the presence of probenecid 
was decreased to the level similar to that obtained in the CHO Flp-In-EV cells (Figure 5.4). 
Unlike the observation in mOat3 expressing cells where all FQs at 1mM test concentrations, 
exhibited significant inhibition of ES uptake, only rufloxacin (~45%) and sparfloxacin (~45%) 
exhibited a significant inhibition of mOat1-mediated PAH uptake, among all the tested FQs 
(Figure 5.4). Again, ciprofloxacin, levofloxacin, lomefloxacin and ofloxacin demonstrated an 
apparent stimulation of the mOat1-mediated transport activity under these experimental 
conditions (Figure 5.4). Hence, as none of the FQs produced strong significant inhibition of 
mOat1-mediated PAH uptake (≥ 50%, as discussed above), no further kinetic analysis was 
performed for this transporter. 
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Figure 5.4. Effect of fluoroquinolones on mouse Oat1-mediated PAH transport  
Uptake of 1 µM [
3
H]PAH was measured at room temperature for 15 min using CHO Flp-In cells 
stably expressing mOat1 in presence of 1 mM unlabeled FQs (black bars). Probenecid (1 mM), 
the prototypical inhibitor of OATs, was used as a negative control for the experiments (black 
bar). The empty-vector transfected CHO Flp-In-EV cells served as a reference for nonspecific 
background substrate accumulation (grey bar). Uptake on the X-axis is expressed as a percentage 
of the positive control (open bar). Values are expressed as means ± S.E.M. and the significant 
differences have been analyzed between the positive control treatment (with no inhibitor) and 
treatments in presence of FQs and probenecid, using one-way ANOVA statistical analysis 
followed by Dunnet‘s post hoc test in GraphPad Prism® version 5.04 (*p<0.05, **p<0.01, 
***p<0.001). All the experiments are conducted at least 3 times performed in triplicate and the 
graphs are single representative experiments. 
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5. C. 4. Interactions of fluoroquinolones with human OAT1 
Similar to mOat1, PAH (1 µM) was used as substrate for hOAT1 (Figure 5.5). The 
accumulation of PAH in the CHO-hOAT1 expressing cells (10.1 ± 0.92 pmol/mg protein/15 
min) was ~5.6 fold greater than that obtained in the control CHO-EV cells (1.78 ± 0.11 pmol/mg 
protein/15 min). The PAH accumulation in the CHO-EV cells was insensitive to the addition of 1 
mM of probenecid (data not shown). In the presence of probenecid, the CHO-hOAT1 cell 
accumulation was decreased to the level similar to that obtained in the control cells (Figure 5.5). 
In these cell lines, rufloxacin (~90%), pefloxacin (~80%), fleroxacin (~70%), lomefloxacin 
(~50%), ofloxacin (~50%) and sparfloxacin (~50%) exhibited a significant inhibition of hOAT1-
mediated PAH uptake (Figure 5.5). Ciprofloxacin, enoxacin, gatifloxacin, moxifloxacin and 
norfloxacin again demonstrated an apparent stimulation of mOat1-mediated transport activity 
under these experimental conditions. On comparing the species orthologs, it was observed that 
sparfloxacin and rufloxacin were the only two FQs which inhibited PAH uptake, while 
ciprofloxacin stimulated PAH uptake by mouse and human OAT1. Gatifloxacin, moxifloxacin 
and prulifloxacin were not found to interact with hOAT1 or mOat1. 
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Figure 5.5. Inhibition of human OAT1-mediated transport by fluoroquinolones   
The uptake of 1 µM [
3
H]PAH was measured at room temperature for 15 min using CHO cells 
stably expressing hOAT1 in presence of 1 mM unlabeled FQs (black bars).  Probenecid (1 mM), 
a prototypical inhibitor of OATs, was used for the experiments as negative control (black bar).  
The empty-vector transfected CHO-EV cells served as reference for nonspecific background 
substrate accumulation (grey bar).  Uptake on the X-axis is expressed as a percentage of the 
positive control (open bar).  Values are expressed as means ± S.E.M. and the significant 
differences were analyzed between the positive control treatment (with no inhibitor) and 
treatments in presence of FQs and probenecid, using one-way ANOVA statistical analysis 
followed by Dunnet‘s post hoc test in GraphPad Prism® version 5.04 (*p<0.05, **p<0.01, 
***p<0.001).  All the experiments are conducted at least 3 times performed in triplicate and the 
graphs are single representative experiments. 
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For the FQs demonstrating significant inhibition of >50%, further kinetic analysis was 
conducted to quantify the strength of inhibition. The concentration-dependency studies were 
conducted for hOAT1 with rufloxacin, pefloxacin and fleroxacin to determine the IC50 values 
(Figure 5.6, Table 5.2). The inhibition of hOAT1-mediated PAH uptake was analyzed in 
presence of increasing FQ concentrations (0.1 - 2,000 µM) and IC50 values were determined by 
nonlinear regression. Rufloxacin demonstrated stimulation of hOAT1-mediated PAH uptake at 
all lower concentrations (0.1, 1, 10, 100, 250, 500 µM) except 1 and 2 mM (~80-90% inhibition, 
similar to that seen above in Figure 5.6), and thus was not considered for further kinetic analysis 
(data not shown). The IC50 values for pefloxacin and fleroxacin were 2252 ± 135 µM and 2228 ± 
84.3 µM respectively. As these FQs were found to be weak inhibitors of hOAT1, lomefloxacin, 
ofloxacin and sparfloxacin showing only ~50% inhibition in the preliminary testing, were not 
analyzed further. 
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Figure 5.6. Determination of inhibition potencies (IC50) for fleroxacin and pefloxacin on 
human OAT1 
 
The uptake of [
3
H]PAH was measured for 1 min at 0-2000 μM of fleroxacin and pefloxacin in 
CHO-hOAT1 cells; Uptake on the Y axis is expressed as a % of the positive control (in absence 
of inhibitor, normalized to 100%) and all points on the inhibition curves are expressed as means 
± S.E.M.  The % inhibitions for all the tested FQs were calculated after correcting for 
nonspecific accumulation in the empty-vector transfected cells, i.e., in CHO-EV cells.  
The IC50 values were determined from non-linear regression (inhibition curves) model using 
GraphPad Prism
®
 version 5.04.  All the experiments are conducted at least 3 times performed in 
triplicate and the graphs are single representative experiments. 
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Table 5.2. Kinetic parameters, unbound Cmax, and calculated drug-drug interaction indices 
for human OAT1 
IC50 value: Half maximal inhibitory concentration value of the FQ inhibitor for the transporter, 
expressed as Mean ± SEM; Unbound Cmax: Unbound maximum plasma concentration obtained 
from preclinical pharmacokinetic studies in healthy humans, after correction for plasma protein 
binding.  Drug-drug Interaction Index: calculated as unbound Cmax/IC50 or Ki; IV: Intravenous 
route of administration. 
  
 IC50 
(µM) 
Unbound Cmax 
(µM) 
Drug-drug 
Interaction Index 
References 
(unbound Cmax) 
Fleroxacin 2228 ± 84 6.8 
(100 mg, IV) 
0.003 (161) 
Pefloxacin 1819 ± 144 8.6 
(400 mg, oral) 
0.005 (40, 114) 
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5. C. 5. Interactions of fluoroquinolones with human OAT4 
As hOAT4 is postulated to be a reabsorptive transporter localized to the apical membrane in 
the RPTC, other than the intracellular pH conditions of the RPTC, it is exposed to a lower pH of 
~6.3, assumed to be the urinary pH conditions. It was predicted from our previous systematic 
review that some FQs could be potentially reabsorbed from the urinary space, back into the 
RPTC.  Hence their interactions with hOAT4 were tested at the physiological (pH = 7.4) as well 
as urinary (pH = 6.3) pH conditions (Figure 5.7).   
In order to study the interaction of FQs with hOAT4, the apically localized transporter in the 
RPTC, ES (1 µM) was used as a substrate (Figure 5.7). The accumulation of ES (positive 
controls at pH 7.4 and 6.3) in CHO-hOAT4 expressing cells (32.9 ± 3.9 pmol/mg protein/15 min 
at pH 7.4, 30.8 ± 2.5 pmol/mg protein/15 min at pH 6.3) was ~5.6 fold and ~3 fold greater than 
that obtained in the control CHO-EV cells (5.9 ± 0.3 pmol/mg protein/15 min at pH 7.4, 10 ± 3.6 
pmol/mg protein/15 min at pH 6.3) at the pH conditions 7.4 and 6.3 respectively. This 
background accumulation by the CHO-EV cells was found to be probenecid-insensitive (~18%) 
(data not shown). In the presence of probenecid, the accumulation of ES in the CHO-hOAT4 
cells was decreased by ~40%. At pH = 7.4, none of the FQs exhibited a significant inhibition of 
hOAT4-mediated ES uptake (Figure 5.7). Also, as seen earlier with other OATs, some FQs like 
moxifloxacin, pefloxacin and prulifloxacin demonstrated a significant stimulation of ES uptake 
by hOAT4. At pH = 6.3, deemed to be more physiologically relevant for the working of hOAT4, 
the ES uptake was found to increase by ~35% as compared to the ES uptake at pH = 7.4 (Figure 
5.7). Moreover, at pH 6.3, in addition to moxifloxacin, pefloxacin and prulifloxacin (stimulated 
ES uptake at pH 7.4), fleroxacin, ofloxacin and rufloxacin also demonstrated stimulation of 
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hOAT4-mediated ES uptake. Due to absence of any strong inhibition of the hOAT4-mediated 
uptake at this pH = 6.3 (≥ 50%, as discussed above), no further kinetic analysis was performed. 
On comparing the FQ effect with hOAT4 at the two pH values (Figure 5.7, Panel C), it can 
be seen that only the interaction of ciprofloxacin, ofloxacin, pefloxacin, and prulifloxacin were 
not sensitive to changes in pH of the extracellular medium (no significant change in ES uptake 
with pH change). All the other FQs significantly increased the hOAT4-mediated ES uptake at pH 
6.3 versus 7.4 (Figure 5.7, Panel C). 
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Figure 5.7. Influence of pH on the interaction of fluoroquinolones with human OAT4 - 
mediated transport 
The uptake of 1 µM [
3
H]ES was measured at room temperature and pH 6.3 (panel A), and pH 
7.4 (Panel B) for 15 min using CHOpro5 cells stably expressing hOAT4 in presence of 1 mM 
unlabeled FQs (black bars); Panel A: 1 µM [
3
H]ES solution at pH 7.4 was used as a control to 
test the influence of pH change on hOAT4-mediated ES uptake in absence of any interacting 
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compounds (dark grey bar);  (Panel A, B): Probenecid (1 mM), a prototypical inhibitor of OATs, 
was used for the experiments as negative control (black bar). The empty-vector transfected 
CHOpro5-EV cells served as a reference for nonspecific background substrate accumulation 
(grey bar). Panel C: Comparison of the effect on FQ interactions with hOAT4 with change in pH 
conditions from 7.4 (open bars) to 6.3 (black bars).  
Uptake on the X-axis is expressed as a percentage of the positive control (open bar). Values are 
expressed as means ± S.E.M. and the significant differences are analyzed between the positive 
control treatment (with no inhibitor) and treatments with FQs/probenecid/ES (at pH 7.4), using 
one-way ANOVA statistical analysis followed by Dunnet‘s post hoc test in GraphPad Prism® 
version 5.04 (*P<0.05, **P<0.01, ***P<0.001). All the experiments are conducted at least 3 
times performed in triplicate and the graphs are single representative experiments;  
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5. D. DISCUSSION: 
Recently, due to the toxicities associated with FQs, there has been an increasing interest in 
understanding the mechanisms governing their in vivo disposition kinetics. Consequently, the 
FQs have been studied for interactions with different transporter families expressed in the body, 
which could potentially mediate their in vivo absorption, distribution, and elimination, and even 
be responsible for clinically significant drug interactions (116). However, additional studies 
would need to be conducted to further elucidate such interactions of FQs with the SLC 
transporters (116). We studied the FQ – OCT interactions in Chapter 4, where none of the FQs 
demonstrated significant interactions with hOCT2; however, gatifloxacin, moxifloxacin, 
prulifloxacin and sparfloxacin were found to be moderate inhibitors of hOCT1, and moxifloxacin 
was the only FQ found to inhibit hOCT3. This study was designed to evaluate the role of OATs 
in the kinetic disposition of the same selected subset of FQs (n=13), using stably transfected cell 
lines expressing mouse and/or human OATs. 
The renally expressed basolateral transporters, hOAT1 and hOAT3 investigated in this study 
are known to function as organic anion/dicarboxylate exchangers using the outwardly directed 
endogenous α-ketoglutarate gradient to drive uptake of anionic subtrates from systemic 
circulation into the RPTC (115, 166, 169, 171). Hence, these OATs might represent a rate-
limiting step for uptake of FQs from the blood circulation (116). Previous work has already 
characterized mOat3 interactions with ciprofloxacin, gatifloxacin, norfloxacin and ofloxacin, as 
well as identified ciprofloxacin and gatifloxacin interactions with hOAT3  (187). This study thus 
tested a larger dataset of FQs, identified from our earlier systemic review with the mouse as well 
as human orthologs of OAT1 as well as hOAT4 (116). The kinetic characterization of the FQs as 
inhibitors for mOat3, allowed an assessment of their inhibition potency for this transporter. 
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Preliminary interaction studies conducted on mOat3 demonstrated significant inhibitory 
interactions of all the tested FQs (Figure 5.1). The kinetically characterized FQs (demonstrating 
≥ 50% inhibition in preliminary studies, Figure 5.1) were found to competitively inhibit mOat3, 
with sparfloxacin showing the strongest inhibition, followed by prulifloxacin, enoxacin, 
levofloxacin, lomefloxacin, fleroxacin and finally moxifloxacin (Figure 5.2 and Table 5.1). A 
similar preliminary interaction study for hOAT3 using the same dataset of FQs, demonstrated a 
substantial difference in the inhibition pattern as compared to mOat3, suggesting possible species 
differences in FQ specificity (Figure 5.3). Ciprofloxacin was found to inhibit mOat3 (~54%) as 
well as hOAT3 (~40%) – mediated ES uptake, which concurred with an earlier observation 
(Figure 5.1 and 5.3; 187). However, gatifloxacin which previously demonstrated a moderate 
hOAT3 interaction, showed no significant interaction in this study (Figure 5.3; 187). Such 
species differences in FQ specificity for the OATs were also evident from the FQ interaction 
studies with mOat1 and hOAT1 (Figure 5.4 and 5.5). For example, fleroxacin and pefloxacin 
were found to be weak inhibitors of hOAT1 with IC50 values of 2252 ± 135 µM and 2228 ± 84.3 
µM, respectively, while they did not interact with mOat1 (Figure 5.4, 5.5 and 5.6, Table 5.2). 
The preliminary inhibition study for hOAT1-FQ interactions demonstrated lomefloxacin to 
inhibit hOAT1-mediated PAH uptake by ~50% (Figure 5.6). This suggested that hOAT1 could 
be the OAT mediating in vivo interactions of the loop diuretic, furosemide (also transported by 
hOAT1) with lomefloxacin (mentioned above), causing decreased CLren and subsequent 
increased AUC∞ for this FQ, with no changes observed in furosemide PK (34, 59, 162).  
In conjunction with the inhibition of OAT-mediated transport, stimulatory effects by some 
FQs on hOAT3, mOat1 and hOAT1-mediated substrate uptake were also observed (Figure 5.3, 
5.4 and 5.5). Such stimulatory effects were found to be sporadic among the tested FQs and were 
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transporter-specific, e.g., mOat3 demonstrated no stimulation of ES uptake in presence of 1 mM 
FQs; while at the same concentrations, enoxacin, levofloxacin, moxifloxacin and prulifloxacin 
stimulated hOAT3-mediated ES uptake (Figure 5.1 and 5.3). The stimulatory effect of 
ciprofloxacin on m/hOAT1-mediated PAH uptake demonstrated in Figure 5.4 and 5.5, was also 
observed in an earlier study (187). Moreover, when these FQs were tested with hOCTs in our 
previous study (Chapter 4), the stimulatory/inhibitory behavior of the FQs also varied between 
the individual hOCTs, exhibiting no consistent pattern (Appendix III). In addition a previous 
study demonstrated sparfloxacin to be a ‗borderline stimulator‘ for MRP2 (ABC transporter) 
mediated transport (130). Such in vitro stimulation also has been observed for different drug 
classes such as steroids, anticancer chemotherapeutics and non-steroidal anti-inflammatory 
drugs, with transporters like OATP1B1 and 1B3 (SLC superfamily) and MRP2 (ABC 
superfamily) (87, 130, 187). These studies have postulated the existence of transporter-specific 
allosteric binding sites for such drug molecules which could stimulate the transporter-mediated 
substrate (another drug or endogenous substrate) uptake, without the drug molecules being 
transported themselves  (Chapter 4; 87, 130). However, some FQs were confirmed to be 
competitive inhibitors for mOat3 (Figure 5.2, Table 5.1) (187). Also, OATs exhibit considerable 
amino-acid sequence identity between species (~78% between mOat3 and hOAT3, ~80% 
between mOat1 and hOAT1) and paralogs (~48% between mOat3 and mOat1, ~49% between 
hOAT3 and hOAT1) (3). Hence such an allosteric binding site (if existing), would be very 
unique for each OAT, and may demonstrate a narrow specificity across the class FQs (as only 
some FQs showed stimulation with m/hOAT1, hOAT3). Overall, the preliminary OAT-FQ 
interaction studies demonstrated that among the tested FQs, only ciprofloxacin exhibited 
similarities in interaction with mouse and human species of OATs, i.e., significant stimulation 
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effects of mOat1 and hOAT1-mediated PAH uptake, and a significant inhibition of mOat3 and 
hOAT3-mediated ES uptake.  No consistent pattern of stimulation or inhibition was observed for 
the other FQs (See Appendix III). In general, these studies suggest that in the mouse/human 
RPTC, OAT/Oat1 and 3 may be involved in the basolateral uptake of some FQs. 
In addition to exploring the FQ interactions with the basolateral OATs, i.e., OAT1 and 3, 
additional analysis was performed to study potential FQ interactions with apically localized 
hOAT4. Though studies have confirmed the apical localization of hOAT4 in human RPTC 
(absent in rodents), its mechanism of action is unclear due to conflicting results indicating its 
function as a facilitated diffusion carrier and an exchanger (15, 32, 57, 186). Thus it is still 
unknown whether hOAT4 mediated exchange mechanism would cause the efflux of drugs from 
the RPTCs into the urinary space, or whether it would result in the tubular reabsorption of 
compounds (57, 186). More recent studies have demonstrated the pH-dependent increase in 
substrate (ES) uptake by hOAT4, and have postulated one of the mechanisms to be facilitating 
reabsorption of compounds by hydroxyl ion exchange (18, 57). Based on this postulated 
mechanism of transport by hOAT4, and our previous systematic review indicating potential renal 
tubular reabsorption of some FQs, we studied whether this transporter could mediate apical 
reabsorption of the FQs. Due to its apical localization in the RPTC, hOAT4 is exposed to a lower 
urinary pH of ~6.3.  Furthermore, literature has suggested that FQ ionic species are sensitive to 
pH change (116).  Thus, in order to identify potential interactions under simulated physiological 
pH conditions, the experiments were conducted at pH ~6.3. Additional experiments were 
conducted at pH = 7.4 to compare the pH-sensitivity of these FQ-hOAT4 interactions. The 
hOAT4-mediated ES uptake in absence of FQs at pH 6.3 (positive control) demonstrated 
stimulation as compared to that at pH = 7.4 (Figure 5.7, Panel B), which was consistent with 
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earlier findings (18, 57). If hOAT4 is considered to transport the FQs by a reabsorptive 
mechanism, then at pH 6.3, the FQ uptake from the extracellular medium would consequently 
decrease the intracellular [H
3
]ES accumulation. On the contrary, our study results demonstrated 
stimulation of hOAT4-mediated ES uptake at this pH (on comparison with the positive control 
treatment at pH =6.3) (Figure 5.7, Panel B and C), with the exception of ciprofloxacin, enoxacin, 
pefloxacin and sparfloxacin, which demonstrated no significant change in ES uptake as a 
function of pH (Figure 5.7, Panel C). These pH-sensitive stimulatory effects shown by hOAT4 in 
presence of FQs could, yet again, be attributed to the potential allosteric binding mechanisms of 
specific FQs with a unique site on hOAT4, similar to that observed with the basolateral OATs 
(explained above).  
In addition to the OATs 1, 3 and 4 which have been identified in our study, other OAT 
paralogs could potentially mediate FQ disposition in the body. For example, OAT2 is known to 
be expressed in humans on the basolateral membrane in the RPTC and on the sinusoidal 
membrane (assumption in literature based on animal immunolocalization studies) in hepatocytes 
(16, 90, 186). Hence, OAT2 could be important for the basolateral uptake of FQs in the RPTC. 
hURAT1, an OAT known to mediate active reabsorption of urate from the urinary space, is also 
known to be localized to the apical membrane in the RPTC (186). This renal OAT could be 
potentially involved in the tubular reabsorption of some FQs, thus affecting their overall CLren 
and t1/2s (Chapter 3). Along with OAT2 mentioned above, hOAT7, a human-specific OAT, is 
also known to be specifically localized in the liver (sinusoidal membrane in hepatocytes) (186). 
As some FQs undergo considerable hepatic metabolism along with renal elimination (e.g., 
sparfloxacin, moxifloxacin), hepatically expressed OATs (i.e., hOAT2 and/or hOAT7) could 
potentially mediate their hepatic uptake and subsequent metabolism. Also, potentially due to 
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higher ‗pre-systemic concentrations‘ (before hepatic first-pass effect) attained by FQs following 
gastrointestinal uptake, OAT2 or OAT7 - mediated hepatic DDIs could potentially occur with 
concomitantly administered drugs/endogenous molecules which are substrates for these 
transporters. However, it is essential to consider that the overall flux governing FQ disposition is 
a ‗net‘ process which is also dependent on individual contributions of other SLC transporter 
members like OCTs, MATEs, OATPs, as well as the ABC transporters (4, 116). Thus any OAT-
FQ interactions would contribute as one of the components driving the overall FQ flux for each 
organ (e.g., renal excretion or potential hepatic metabolism). 
Following the identification and in vitro characterization of FQ interactions with OATs, a 
quantitative assessment was conducted to determine whether these OATs could potentially 
mediate any clinically relevant FQ DDI on concomitant administration of other drugs which are 
OAT substrates/inhibitors, for example, probenecid and furosemide (39, 42, 59, 75, 95, 149, 157, 
187, 197). Based on the recent DDI guidance drafted by the FDA 
(http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/u
cm292362.pdf), the ratio of unbound maximum concentration (unbound Cmax) to Ki or IC50 
values of the drugs (DDI index) (See Chapter 4; 73) were calculated for hOAT1 and mOat3. A 
DDI ratio ≥ 0.1 is suggested to indicate that the transporter-mediated DDI would achieve clinical 
relevance and additional in vivo DDI studies will have to be conducted with the co-administered 
drugs before obtaining FDA approval (73). Thus, unbound Cmax values were calculated by 
compiling the human (for hOAT1) and mouse (for mOat3) in vivo pharmacokinetic and protein 
binding studies for each FQ as shown in Tables 5.1 and 5.2. Further, the DDI indices were 
calculated for FQ interactions with hOAT1 and mOat3 (187). As can be seen from Table 5.1 and 
5.2, all the DDI indices were < 0.1, indicating that interactions of these FQs with OATs may not 
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result in clinically relevant DDIs. Nevertheless, this study has indeed identified an important 
component for the pathway of renal elimination of this dataset of FQs. Such in vitro transport 
studies would need to be conducted for the newer marketed FQs, as well as for those under 
development, in order to design safer antimicrobials and reduce the occurrence of any new DDIs.  
Although only some FQs demonstrated significant inhibition interactions with the human 
OAT-mediated substrate transport, further consideration is needed for the unanticipated 
stimulatory effects demonstrated by the other FQs (Figures 5.3, 5.4, 5.5 and 5.7). If such 
observations are truly a result of allosteric binding mechanisms, then in such a scenario, 
concomitant use of FQs with OAT substrates (victim drugs) could potentially cause increased 
renal elimination (in case of hOAT1 and 3) or reabsorption (for hOAT4) of the interacting 
substrates (victim drug), with no significant effect on the ‗OAT-mediated elimination‘ of FQs. 
This could subsequently affect the systemic concentrations of the ‗victim‘ drugs, further 
increasing/decreasing their efficacies (depending on the site of action) and/or causing potential 
toxicities. For example, consider a drug like the loop diuretic – furosemide, known to be 
transported by hOAT1 (IC50 = 18 ± 1.1 µM), hOAT3 (IC50 = 7.3 ± 0.81 µM), as well as hOAT4 
(IC50 = 44.5 ± 2.53 µM) (34, 59, 184). In such a case, if a FQ causing stimulation of hOAT1, 
e.g., ciprofloxacin (FQs with considerable renal elimination), is co-administered with 
furosemide, it may result in increased renal basolateral uptake of furosemide due to 
ciprofloxacin-mediated hOAT1 stimulation (See Figure 5.5). Similarly effect may be seen when 
a FQ found to stimulate hOAT3 (e.g., levofloxacin) (Figure 5.3) is co-administered with 
furosemide. Assuming that the apical efflux transporters like MRP4 and BCRP (known to 
transport furosemide) (60) are uninhibited by the FQs in such a DDI scenario, this may result in 
increased urinary concentrations of furosemide, further causing an enhanced natriuretic effect by 
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this diuretic (34, 184). On the contrary, co-administration of a FQ like ofloxacin (stimulated 
hOAT4, Figure 5.7, Panel B) with furosemide may increase the hOAT4-mediated reabsorption 
of furosemide, further decreasing its natriuretic effect due to lower concentrations in the urine 
(34, 59, 184). However, as the in vivo scenario includes multiple transporters (uptake and efflux) 
mediating renal transport of furosemide as well as these FQs, such effects may be 
counterbalanced during their transcellular flux, producing no ―net‖ significant impact on 
furosemide PK and resultant pharmacodynamic response. Although the clinical implications of 
such stimulatory effects of FQs have not been assessed, these may have an important role 
especially in multi-drug regimen interactions (poly-pharmacy) where due to inhibition of 
multiple transporters by different drugs, such stimulation of substrate transport may exhibit 
enhanced activity/toxic effects.  
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CHAPTER 6 
 
OVERALL CONCLUSIONS AND FUTURE DIRECTIONS 
 
 
 
 
Due to their wide spectrum of antimicrobial activity, longer durations of action and 
general availability, FQs rank among the most highly prescribed medications for the past thirty 
years (9). As a class, FQs exhibit intestinal, hepatic, and renal elimination; with renal excretion 
representing a major component in determining the systemic and urinary concentrations of many 
of these agents. In the course of FQ development, there has been accumulating evidence 
establishing a clear role for active transport mechanisms in their systemic disposition. However, 
until recently, work aimed at identifying the specific transport mechanisms/transporters involved 
in FQ kinetics has been limited. It now appears that multiple members from the ABC and SLC 
transporter superfamilies play an active role in FQ disposition, not only in renal elimination, but 
also in the overall flux of these zwitterionic molecules in the body. This information, in turn, 
provides potential explanations, at the molecular level, for clinically observed drug-drug 
interactions, organ-specific adverse effects, and inter-patient variability in FQ pharmacokinetics 
and pharmacodynamics. As indicated by the results of our systematic review (discussed in 
Chapter 3), for some FQs the renal handling appears to be the driving force behind the 
differences in their duration of action and clinical dose frequency. This dissertation thus intended 
to study the role of SLC22 transporter family members in the ‗net‘ renal tubular 
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secretion/reabsorption (i.e., CLren,tub) of a selected dataset of FQs (identified from the systematic 
review discussed in Chapters 2 and 3). Further, the in vitro studies (Chapter 4 and 5) 
characterizing the interactions between FQs and the OCTs and OATs (Figure 1.2), allowed an 
assessment of the in vivo contribution of these transport proteins to the net renal elimination of 
these antimicrobials, as well as identified transporters potentially influencing their overall 
absorption, distribution, metabolism and elimination. These in vitro studies examining FQ-OCT 
interactions (discussed in Chapter 4), demonstrated that hOCT1 and hOCT3 are likely to mediate 
the renal basolateral uptake of some FQs. Based on its localization, hOCT3 may be involved in 
the intestinal and hepatic uptake of moxifloxacin (Figures 4.4 and 4.5, Table 4.1). Due to its 
abundant expression in the liver (basolateral membrane), hOCT1 could mediate the hepatic 
uptake of gatifloxacin, moxifloxacin, prulifloxacin and sparfloxacin, amongst others, for which a 
preliminary interaction was detected (Figures 4.1, 4.2 and 4.6, Table 4.1). Also, as hOCT1 is 
expressed on the basolateral membrane in the enterocytes (Figure 4.6), this transporter could also 
potentially mediate the intestinal uptake of FQs from the ‗presystemic‘ blood circulation (prior to 
first-pass metabolism), further facilitating GI efflux of these FQs by the apically localized ABC 
transporters and reducing their bioavailability (4, 14, 23, 40, 52, 96, 148, 205). Moreover, 
hOCT1 could potentially be a rate-limiting transporter for FQ prodrugs like prulifloxacin, 
wherein its metabolic conversion (to active metabolite, ulifloxacin) would be an essential step to 
elicit an in vivo therapeutic action (discussed in Chapter 4).  
In the in vitro studies with renally expressed human and mouse orthologs of OATs 
(Chapter 5), some of the FQs moderately inhibited OAT-mediated transport activity. The studies 
demonstrated that due to its abundant renal expression (basolateral membrane), hOAT1 may be 
involved in the uptake of FQs like fleroxacin and pefloxacin from the systemic circulation 
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(Figure 5.6, Table 5.2). However, in mice, renally expressed mOat3 was more likely to be 
involved in the basolateral uptake of FQs like enoxacin, fleroxacin, levofloxacin, lomefloxacin, 
moxifloxacin, prulifloxacin and sparfloxacin; with varying affinities (Figure 5.2, Table 5.1). 
Transporters such as hOAT3 and mOat1 demonstrated only moderate interactions with the FQs. 
Some moderate OAT-mediated interactions (e.g., ciprofloxacin with hOAT3, lomefloxacin with 
hOAT1) also further allowed identification of the transport pathways likely to mediate the 
clinically observed DDIs (e.g., lomefloxacin with furosemide; ciprofloxacin with probenecid), 
and thus indicated their involvement in the renal elimination of FQs (75, 95, 162). Additionally, 
the studies with human and mouse orthologs of OATs demonstrated the existence of species 
differences in selectivity and relative affinities of the FQs for OAT1 and OAT3 - mediated 
transport (hOAT1 versus mOat3, hOAT1 versus mOat1).  
In addition to the OATs encompassed by this dissertation, such FQs interactions have yet 
to be studied for renally expressed hURAT1 (SLC22A12), which is known to be localized to the 
apical membrane in the RPTC, and is involved in active tubular reabsorption of urate from the 
urinary space (186). This transporter could potentially mediate the renal tubular reabsorption of 
FQs, thus explaining the prolonged t1/2s for some FQs. In addition, hOAT2 known to be 
expressed in RPTC (basolateral membrane) and hepatocytes (sinusoidal membrane), as well as 
hOAT7 (human-specific, hepatically expressed on sinusoidal membrane) could potentially 
mediate the hepatic uptake of FQs, further affecting their metabolism and/or renal uptake.  
Following identification of the significant inhibitory interactions of selected FQs with the 
OCTs and OATs, DDI indices were calculated for hOCT1, hOCT3, hOAT1, and mOat3. This 
DDI index analysis enabled a quantitative assessment of the potential of these SLC22 
transporters to mediate clinically relevant DDIs for FQs, according to the FDA DDI draft 
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guidance: 
(http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/u
cm292362.pdf) (discussed in Chapters 4 and 5, Table 4.1, 5.1 and 5.2). However, the DDI 
indices suggested that these SLC22 transporters are not likely to be involved in causing clinically 
relevant DDIs on co-administration of the tested FQs with other OAT/OCT substrates or 
inhibitors. In addition, the impact of mOat3 on the renal elimination of some FQs (enoxacin, 
norfloxacin, moxifloxacin, sparfloxacin) was assessed, by analyzing the relationship between 
CLren
u 
of FQs in mice (obtained from preclinical data) and their respective Ki values for mOat3. 
The results demonstrated no significant relationship (See Appendix IV) (187). These 
observations suggested that although the SLC22 transporters are potentially involved in the 
systemic disposition of FQs, they may not be the rate-limiting step. This might be attributed to 
the physiological interplay of different transporter gene families (ABC as well as SLC 
transporters) that mediate the pathways governing overall FQ kinetics, a result of which, being 
no single transporter represents the rate-limiting step in their renal/hepatic elimination. 
Assessments of clinical DDI indices lead to similar conclusion. For example, the clinical DDI 
studies with concomitant administration of FQs and probenecid demonstrated only ~25-60% 
decrease in CLren (42, 75, 95, 149). Probenecid has exhibited in vitro inhibition of OATs, OATPs 
(rat Oatp1 and 2), MDR1 (weak inhibition), and MRPs (MRP2, 4 and 5); and has been shown to 
completely shut down in vitro OAT – mediated transport (~100% inhibition: Figure 5.1, 5.3) (25, 
45, 77, 133, 163). These results may indicate that on concomitant administration of probenecid 
and FQs, despite the inhibition anion transporters, FQ kinetics could be mediated by uninhibited 
cation/zwitterion transporters such as OCTs, OCTNs and MATEs, known to interact with these 
antimicrobials (116). Similar results were found with the cation/zwitterion SLC transporters 
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upon FQs combination with cationic drugs like cimetidine (26, 42, 111, 146, 150). Under these 
conditions, FQ kinetics might largely be mediated by the uninhibited anion and ABC efflux 
transporters (116). These data indicate that the resultant PK endpoints obtained in our systematic 
review (discussed in Chapter 3) might represent the ‗combined function‘ of multiple transporters, 
from a variety of gene families, expressed in several tissues. Such a ‗combined functioning‘ of 
transporters establishing the ultimate in vivo distribution profile of a given substrate, could be 
tested by determining the effects of probenecid and cimetidine co-administration on the overall 
kinetics of FQ disposition. However, clinical studies may not investigate such interactions, 
considering the safety and toxicities associated with the FQs. 
An unexpected observation in the in vitro studies (Chapters 4 and 5) was the stimulation 
of OCT- and OAT`- mediated transport by some FQs. Some previous studies also demonstrated 
FQ stimulation of transport activity including sparfloxacin as a stimulator of MRP2 (ABC 
transporter), ciprofloxacin causing stimulation of mOat1- and hOAT1- mediated PAH uptake 
(130, 187). Such stimulatory mechanisms by FQs could have potentially significant clinical 
manifestations by increasing the clearance (i.e., decreasing the t1/2) of the ‗victim‘ (interacting) 
drugs (Chapter 4 and 5). This observation may be of particular importance in cases where multi-
drug regimens are administered to patients. Future investigations could explore such stimulatory 
mechanisms in vivo, for example, determining if co-administration of FQs and PAH increases 
renal PAH clearance or co-administration of FQ and metformin (OCT substrate) accelerates 
metformin clearance, and to explore if these mechanisms could in fact have any significant 
clinical implications in multiple-drug interactions.  
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These in vitro studies have only explored FQs as inhibitors for the SLC22 transporters, 
leaving open the question of whether they are actual substrates. Thus, future studies should 
assess whether cellular accumulation can be confirmed.  
It would also be of interest to study the molecular-level binding characteristics of FQs 
with the transport proteins. Quantitative structure-activity relationship (QSAR) and comparative 
molecular field analysis (CoMFA) studies could aid in identifying the key factors influencing the 
sporadic inhibition/stimulation mechanisms seen with the individual FQs, and allow the 
prediction of any allosteric binding mechanisms of these agents with these transporters (24, 79, 
94). Finally, although this study has functionally characterized that FQs are likely be moderate 
inhibitors of the SLC22 transporters, the impact of various physiological (endogenous substrates 
and xenobiotics, protein binding, pH conditions) and genetic (SLC22 single nucleotide 
polymorphisms (SNPs)) factors could affect (increase/decrease) the ‗apparent‘ affinities of these 
agents for the transporters (71, 83, 180). Nevertheless, the existence of such transporter SNPs as 
well as disease states in patient populations could potentially make such moderate FQ-transporter 
interactions more clinically relevant. 
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APPENDIX I 
 
 
SUMMARY OF HUMAN PHARMACOKINETIC STUDIES FOR FLUOROQUINOLONES 
 
1. AMIFLOXACIN: 
 
Study Population BW 
(kg) 
Dose 
and 
Route 
(mg) 
Sampling 
Schedule 
Assay LOQ PK 
Analysis 
PK Endpoints 
    Plasma Urine  Plasma Urine  AUC 
(mg*min/
ml) 
Vdss 
(L/kg) 
CLtot 
(ml/min
/kg) 
CLren 
(ml/min/kg) 
Cook 
JA et. 
al.(21) 
Healthy, n 
= 48 males. 
18-46 yrs 
62-
102 
kg 
400, 
oral 
0-12 hrs 0-24 
hrs 
HPLC 
with 
UV 
0.10-5 
µg/ml 
0.5-
100 
µg/ml 
Non-
compart-
mental 
1.34 - - 99 ± 14 
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2. ANTOFLOXACIN: 
 
 
Study Population BW 
(kg) 
Dose and 
Route 
(mg) 
Sampling 
Schedule 
Assay LOQ PK 
Analysis 
PK Endpoints 
Plasma Urine Plasma Urine AUC 
(mg*min
/ml) 
Vdss 
(L/kg) 
CLtot 
(ml/min
/kg) 
CLren 
(ml/min/kg) 
Wang J 
et. al. 
(194) 
Healthy, n 
= 12 males. 
20-28 yrs 
52-
70 
400, IV 
Infusion 
over 120 
min 
(1mg/ml) 
0-96 hrs 0-96 
hrs 
HPLC 
with 
UV 
37 
µg/ml 
40 
µg/ml 
Non-
compart-
mental 
3.23 3.72 2.1 1.22 
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3. CIPROFLOXACIN: 
 
Study Population BW 
(kg) 
Dose and 
Route 
(mg) 
Sampling 
Schedule 
Assay LOQ PK 
Analysis 
PK Endpoints 
Plasma Urine Plasma Urine AUC 
(mg*min
/ml) 
Vdss 
(L/kg) 
CLtot 
(ml/min/
kg) 
CLren 
(ml/min/
kg) 
Lettieri 
JT et. 
al.(97) 
Healthy, n 
= 12 males. 
27.4 ± 4.3 
yrs 
73 ± 
6.7 
300 or 400 
mg, IV 
Infusion 
over 60 
min (200 
ml 
volume) 
0-24 hrs 0-24 
hrs 
HPLC 0.025-5.0 
µg/ml 
0.025-
5.0 
µg/ml 
Non-
compart-
mental and 
two 
Compart-
mental 
0.52  (300 
mg) 0.68  
(400 mg) 
2.44 
(300 
and 400 
mg) 
8.26  
(300 mg) 
8.18  
(400 mg) 
 
5.32 (300 
mg) 4.9   
(400 mg) 
Wingen
der W 
et. 
al.(199) 
Healthy, n 
= 6 males. 
29 ± 9 yrs 
 
 
 
 
 
 
 
 
75 ± 
11 
100 mg IV 
bolus 
(with 
infusion 
pump 
within 5 
min) 
0-48 hrs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0-48 
hrs 
Micro-
biolog-
ical 
assay 
and 
HPLC 
0.01 
µg/ml 
 
0.05 
µg/ml 
Mammillary 
three 
compart-
mental open 
model 
0.1456 1.98 ± 
0.4 
9.62 ± 
0.93 
 
 
 
 
 
 
 
 
 
4.42 ± 
0.43 
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Study Population BW 
(kg) 
Dose and 
Route 
(mg) 
Sampling 
Schedule 
Assay LOQ PK 
Analysis 
PK Endpoints 
Plasma Urine Plasma 
 
Urine AUC 
(mg*min
/ml) 
Vdss 
(L/kg) 
CLtot 
(ml/min/
kg) 
CLren 
(ml/min/
kg) 
Höffken 
G et al. 
(64) 
Healthy, n 
= 12 Males 
and 
Females, 
22-34 yrs 
51 - 
80.5 
50 or 100 
mg IV 
infusion 
(with an 
infusion 
pump over 
15 min) 
0-105 
min 
and 2-
24 hrs 
0-24 
hrs 
Micro-
biolog-
ical 
Assay 
and 
HPLC 
0.008 
µg/ml 
with K. 
pneumo
niae and 
0.07 
µg/ml 
with B. 
subtilis 
0.2 
µg/ml 
(HPLC) 
Open two 
and three 
compart-
mental 
models 
0.072 (50 
mg) 0.18 
(100 mg) 
- 18 (50 
mg) 
13.89 
(100 mg) 
11.14 (50 
mg) 8.78 
(100 mg) 
Davis R 
et. al. 
(27) 
Healthy, n 
= 12 Males, 
23-32 yrs 
75.9
± 
8.5 
200 mg IV 
infusion 
over 30 
min 
0-45 
min 
and 1-
24 hrs 
0-48 
hrs 
HPLC 0.02 
µg/ml 
0.01 
µg/ml 
Non-
compart-
mental 
0.383 2.25 ± 
0.48 
7.02 4.57 
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4. ENOXACIN: 
 
Study Population BW 
(kg) 
Dose and 
Route 
(mg) 
Sampling 
Schedule 
Assay LOQ PK 
Analysis 
PK Endpoints 
Plasma Urine Plasma Urine AUC 
(mg*min
/ml) 
Vdss 
(L/kg) 
CLtot 
(ml/min/
kg) 
CLren 
(ml/min/
kg) 
Misiak 
PM et. 
al. 
(111) 
Healthy, n 
= 10, Male 
and female, 
19 -52 yrs 
56.4
–
98.4 
400 mg, 
IV 
Infusion 
over 60 
min 
0-48 hrs 0-48 
hrs 
HPLC 0.1 µg/ml 3.0 
µg/ml 
Non-
compart-
mental 
1.056 2.0 5.14 2.86 
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5. FLEROXACIN: 
 
Study Population BW 
(kg) 
Dose and 
Route 
(mg) 
Sampling 
Schedule 
Assay LOQ PK 
Analysis 
PK Endpoints 
Plasma Urine Plasma Urine AUC 
(mg*min
/ml) 
Vdss 
(L/kg) 
CLtot 
(ml/min/
kg) 
CLren 
(ml/min/
kg) 
Stuck 
AE et. 
al. 
(161) 
Healthy, n 
= 6, Male 
and female, 
25-58 yrs 
52– 
74 
100 mg, 
IV 
Infusion 
over 20 
min 
0-60 
min and 
2-72 hrs 
0-96 
hrs 
HPLC 20  ng/ml 20 
ng/ml 
Non-
compart-
mental 
1.14 1.4 ± 
0.34 
1.41 ± 
0.23 
0.93 ± 
0.3 
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6. GATIFLOXACIN: 
 
Study Population BW 
(kg) 
Dose and 
Route 
(mg) 
Sampling 
Schedule 
Assay LOQ PK 
Analysis 
PK Endpoints 
Plasma Urine Plasma Urine AUC 
(mg*min/
ml) 
Vdss 
(L/kg) 
CLtot 
(ml/min/
kg) 
CLren 
(ml/min/
kg) 
Gajjar 
DA 
et. al. 
(43) 
Healthy, n 
= 40 (8 in 
each study 
group), 
Male and 
female, 18-
45 yrs 
61-96 400  mg, 
IV 
Infusion 
over 60 
min 
0-72 hrs 0-24 
hrs 
HPLC Not mentioned Non-
compart-
mental 
1.72 1.5 ± 0.2 2.62 2.17 
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7. GEMIFLOXACIN: 
 
Study Population BW 
(kg) 
Dose and 
Route 
(mg) 
Sampling 
Schedule 
Assay LOQ PK 
Analysis 
PK Endpoints 
Plasma Urine Plasma Urine AUC 
(mg*min
/ml) 
Vdss 
(L/kg) 
CLtot 
(ml/min/
kg) 
CLren 
(ml/min/
kg) 
Allen A 
et. al. 
(2) 
Healthy, n 
= 19 (n=4 
received 
this dose), 
Male, 18-
45 yrs 
21-
41 
160  mg, 
oral 
0-48 hrs 0-24 
hrs 
HPLC 0.01 
µg/ml 
1.0 µg/ml Non-
compart-
mental 
0.33 - - 2.1 
Allen A 
et. al. 
(1) 
Healthy, n 
= 22, Male 
and female, 
18-60 yrs 
- 320  mg, 
oral 
0-48 hrs Pre-
dose 
on 
Day 1 
and 
day 5 
HPLC 0.01 
mg/ml 
0.01 
mg/ml 
Non-
compart-
mental 
0.312 - - 4.53 
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8. GREPAFLOXACIN: 
 
Study Population BW 
(kg) 
Dose 
and 
Route 
(mg) 
Sampling 
Schedule 
Assay LOQ PK 
Analysis 
PK Endpoints 
Plasma Urine Plasma Urine AUC 
(mg*min/
ml) 
Vdss 
(L/kg) 
CLtot 
(ml/min
/kg) 
CLren 
(ml/min/kg) 
Efthym
iopoulo
s, C. et 
al. (31) 
Healthy, 
male and 
female, n = 
18, 21-37 
yrs 
70-
89 
200, 400, 
600, 800, 
1200  
mg, oral 
0-72 hrs 0-72 
hrs 
HPLC 0.00466 
µg/ml 
0.0046
6 µg/ml 
Non-
compart-
mental 
0.31 
(200mg), 
0.68 (400 
mg), 1.18 
(600 mg), 
1.66 (800 
mg), 
2.7(1200 
mg) 
 
- - 0.5 (200 
mg), 0.66 
(400, 600, 
800 mg), 
0.83 (1200 
mg) 
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9. LEVOFLOXACIN: 
 
Study Population BW 
(kg) 
Dose 
and 
Route 
(mg) 
Sampling Schedule Assay LOQ PK 
Analysis 
PK Endpoints 
Plasma Urine Plasma Urine AUC 
(mg*min
/ml) 
Vdss 
(L/kg) 
CLtot 
(ml/min/
kg) 
CLren 
(ml/min/
kg) 
Chow 
AT. et 
al. 
(19) 
Healthy, 
male and 
female, n = 
18 (n=4 
with normal 
renal 
functions 
assessed), 
26-54 yrs 
- 750  
mg, IV 
Infu-
sion 
over 
1.5 hrs 
0-72 hrs Not 
deter-
mined 
HPLC Not 
men-
tioned 
(valida-
tion 
range: 
0.125-
13.75 
µg/ml) 
Not 
deter-
mined 
Two 
Compart-
mental 
using 
linear 
disposi-
tion 
4.04 1.51 2.66 - 
Chien 
SC et. 
al. 
(17) 
Healthy, 
male, n = 
18 (10 for 
IV), 18-55 
(20-44 for 
IV 
levofloxaci
n treatment) 
yrs 
94.4 ± 
10.5 
500  
mg, IV 
Infu-
sion 
with 
infu-
sion 
pump 
over 60 
min 
0, 0.5, 1 
hr (during 
IV inf.) 
and 0.5-
60 hrs 
post-
treatment 
8hrs 
prior to 
dosing, 
0-48 
hrs 
post- 
dosing 
HPLC Not 
men-
tioned 
(valida-
tion 
range: 
0.082-
10.5 
µg/ml) 
Not 
men-
tioned 
(valida-
tion 
range: 
2-1132 
µg/ml) 
Non-
compart-
mental 
3.32 0.94 1.66 1.01 
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LOMEFLOXACIN: 
 
Study Population BW 
(kg) 
Dose 
and 
Route 
(mg) 
Sampling 
Schedule 
Assay LOQ PK 
Analysis 
PK Endpoints 
Plasma Urine Plasma Urine AUC 
(mg*min/
ml) 
Vdss 
(L/kg) 
CLtot 
(ml/min
/kg) 
CLren 
(ml/min
/kg) 
Gros I. 
et al. 
(53) 
Healthy, 
female, n = 
6, 26-49 
yrs 
50-67 400  
mg, oral 
0-24 hrs 0-24 hrs HPLC 0.05 
µg/ml 
2 µg/ml Open 
Two 
Compart-
mental 
model 
2.22 - - 2.06 
Stone 
JW et. 
al. 
(160) 
Healthy, 
male, n = 6, 
24-42 yrs 
68-81 400  
mg, oral 
0-90 
min and 
2 –25 
hrs 
post-
dosing 
0 —48 
hrs 
Antibiotic 
assay 
(plate 
diffusion 
method) 
and HPLC 
(serum 
samples 
from 2 
volunteers
) 
0.25 
µg/ml 
(plate 
diffusion 
assay), 
HPLC: < 
0.12 
µg/ml 
0.25 
µg/ml) 
(plate 
diffusion 
assay) 
Open 
Two 
Compart-
mental 
linear  
model 
1.93 - - 2.09 
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10. MOXIFLOXACIN: 
 
Study Population BW 
(kg) 
Dose 
and 
Route 
(mg) 
Sampling 
Schedule 
Assay LOQ PK 
Analysis 
PK Endpoints 
Plasma Urine Plasma Urine AUC 
(mg*min
/ml) 
Vdss 
(L/kg) 
CLtot 
(ml/min
/kg) 
CLren 
(ml/min
/kg) 
Siefert 
HM et. 
al. 
(145) 
Healthy, 
male adults 
85 
(aver
age) 
102 
mg, IV 
infu-
sion 
over 30 
mins 
0-48 hrs - HPLC  
and radio-
active 
scintilla-
tion 
Not specified 
for human 
assay (0.005 
µg/ml for 
animal 
plasma 
samples) 
- (radio-
active 
method 
used) 
Non-
compart-
mental 
0.54 2 ± 
1.08 
2.2 0.43 
Stass H 
et. al. 
(158) 
Healthyn = 
12, male,  
23-41 yrs 
71-
112 
400  
mg, IV 
infu-
sion 
over 1 
hr 
0-1hr 
during 
infusion, 
and 1.5 – 
96 hrs 
post-
dosing 
0 —
96 hrs 
HPLC 2.5 µg/ml 2.5 
µg/ml 
Non-
compart-
mental 
2.08 2.05 ± 
1.15 
2.27 0.51 
 
  
  
139 
 
11. NORFLOXACIN:  
 
 
Study Population BW 
(kg) 
Dose 
and 
Route 
(mg) 
Sampling 
Schedule 
Assay LOQ PK 
Analysis 
PK Endpoints 
Plasma Urine Plasma Urine AUC 
(mg*min/
ml) 
Vdss 
(L/kg) 
CLtot 
(ml/min
/kg) 
CLren 
(ml/min
/kg) 
Eandi 
M et. 
al. (30) 
Healthy n = 
12 (6 were 
healthy), 
male and 
female, 26-
31 yrs 
54-
72 
400 
mg, 
oral 
0-12 hrs 0-24 
hrs 
Liquid 
chromat-
ography 
Not 
mentioned 
(final range: 
0.31 -5.0 
µg/ml) 
Not 
men-
tioned 
(final 
range: 
50 -600 
µg/ml) 
Non-
compart-
mental 
0.27 - - 7.47 
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12. OFLOXACIN: 
 
Stud
y 
Population BW 
(kg) 
Dose 
and 
Route 
(mg) 
Sampling 
Schedule 
Assay LOQ PK 
Analysis 
PK Endpoints 
Plasma Urine Plasm
a 
Urine AUC 
(mg*min/
ml) 
Vdss 
(L/kg) 
CLtot 
(ml/min/kg) 
CLren 
(ml/min/kg) 
Lode 
H et. 
al. 
(99) 
Healthy n = 
18, male 
and female, 
25-46 yrs 
54-
74 
25, 50, 
100, 
200 
mg, IV 
infused 
during 
30 min 
0-2 hrs 
and at 
3-72 hrs 
post-
dosing 
0-72 
hrs 
post-
dosing 
Liquid 
chromato
-graphy 
Detect
ion 
limits: 
20 
µg/ml 
Detect
ion 
limits: 
200 
µg/ml 
Oral two 
and three 
compart-
mental 
model 
0.09 (25 
mg), 0.19 
(50 mg), 
0.44 (100 
mg), 0.86 
(200 mg) 
- 4.3 (25 mg), 
4.2 (50 mg), 
3.5 (100, 
200 mg) 
3.7 (25 mg), 
3.42 (50 
mg), 2.8 
(100 mg), 
2.88 (200 
mg) 
 
  
  
141 
 
13. PEFLOXACIN: 
 
Study Population BW 
(kg) 
Dose 
and 
Route 
(mg) 
Sampling 
Schedule 
Assay LOQ PK 
Analysis 
PK Endpoints 
Plasma Urine Plasma Urine AUC 
(mg*min
/ml) 
Vdss 
(L/kg) 
CLtot 
(ml/min/kg) 
CLren 
(ml/min/kg) 
Montay 
G et. al. 
(114) 
Healthy n = 
6, male and 
female, 19-
29 yrs 
54-
75 
400 
mg, 
oral 
0-24 hrs 0-72  
hrs 
post-
dosing 
Biolog-
ical, 
Fluori-
metric 
assay 
and 
HPLC 
0.1 
µg/ml 
(Fluori-
metric 
assay) 
Not 
men-
tioned 
Oral two 
and three 
compart-
mental 
model 
2.89 - - 0.19 
 
  
  
142 
 
14. RUFLOXACIN: 
 
Study Population BW 
(kg) 
Dose 
and 
Route 
(mg) 
Sampling 
Schedule 
Assay LOQ PK 
Analysis 
PK Endpoints 
Plasma Urine Plasma Urine AUC 
(mg*min/
ml) 
Vdss 
(L/kg) 
CLtot 
(ml/min
/kg) 
CLren 
(ml/min/kg) 
Kisicki 
JC et. 
al. (89) 
Healthy n = 40, 
male, 19-29 yrs 
54-
75 
400 
and 
600 
mg, 
oral 
0-12 hrs 0-24  
hrs 
HPLC 0.05 
µg/ml 
0.05 
µg/ml 
One 
compart-
mental open 
model 
10.56 (400  
mg), 16.63 
(600 mg) 
- - 0.27 (400 
mg), 0.3 
(600 mg) 
Perry G 
et. al. 
(131) 
Healthy  n = 
24, male and 
female, n=6 
assessed with 
creatinine 
clearance > 80 
ml/min/ 1.73 
m
2
, 40 ± 7 yrs 
70 ± 
4 
400 
mg, 
oral 
0-96 hrs 0-96  
hrs 
HPLC 0.5 
µg/ml 
0.3 
µg/ml 
two 
compart-
mental open 
model with 
first order 
input and 
elimination 
9.24 - - 0.24 
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15. SPARFLOXACIN: 
 
Study Population BW 
(kg) 
Dose 
and 
Route 
(mg) 
Sampling 
Schedule 
Assay LOQ PK 
Analysis 
PK Endpoints 
Plasma Urine Plasma Urine AUC 
(mg*min/
ml) 
Vdss 
(L/kg) 
CLtot 
(ml/min
/kg) 
CLren 
(ml/min/kg) 
Montay 
G et. al. 
(113) 
Healthy n = 
12, male, 20-
28 yrs 
70 ± 
6.8 
200, 
400, 
600 
and 
800 
mg, 
oral 
0-120 
hrs 
0-120  
hrs 
HPLC 15 
ng/ml 
250 
ng/ml 
Non- 
compart-
mental 
model 
1.13 (200  
mg), 1.96 
(400 mg), 
2.75 (600 
mg), 3.45 
(800 mg) 
- - 0.27 (200 
mg), 0.28 
(400, 600 
mg), 0.29 
(800 mg) 
Fillastre 
JP et. Al. 
(36) 
Healthy  n = 
20, male and 
female, n=6 
assessed with 
creatinine 
clearance 
between 75-
133 ml/min/ 
1.73 m
2
, 55 ± 
10 yrs 
70 ± 
11 
400 
mg, 
oral 
0-120 
hrs 
0-120  
hrs 
HPLC 15 
ng/ml 
250 
ng/ml 
Non- 
compart-
mental 
model 
1.89 - - 0.3 
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16. TEMAFLOXACIN: 
 
Study Population BW 
(kg) 
Dose 
and 
Route 
(mg) 
Sampling 
Schedule 
Assay LOQ PK 
Analysis 
PK Endpoints 
Plasma Urine Plasma Urine AUC 
(mg*min/
ml) 
Vdss 
(L/kg) 
CLtot 
(ml/min
/kg) 
CLren 
(ml/min/kg) 
Grannem
an RG 
et. al. 
(51) 
Healthy n = 
30, male, 19-
28 yrs 
60-89 100, 
200, 
400, 
600 
and 
800 
mg, 
oral 
0-60 hrs 0-60  
hrs 
HPLC 0.01 
µg/ml 
0.01 
µg/ml 
Non- 
compart-
mental 
model and 
one-
compart-
mental open 
model 
0.45 (100 
mg), 0.90 
(200  mg), 
1.78 (400 
mg), 2.97 
(600 mg), 
3.52 (800 
mg) 
- - 1.76 (100 
mg), 1.82 
(200 mg), 
1.75 (400, 
1.33 (600 
mg), 1.75 
(800 mg) 
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17. TROVAFLOXACIN:  
 
 
Study Population BW 
(kg) 
Dose 
and 
Route 
(mg) 
Sampling 
Schedule 
Assay LOQ PK 
Analysis 
PK Endpoints 
Plasma Urine Plasma Urine AUC 
(mg*min
/ml) 
Vdss 
(L/kg) 
CLtot 
(ml/min/kg) 
CLren 
(ml/min/kg) 
Vincent 
J et. al. 
(192) 
Healthy n = 
16, male, 
18-42 yrs 
64- 
90.7 
30, 
100, 
200, 
300 
mg, IV 
infu-
sion 
over 1 
hr 
0-73 hrs 0-72  
hrs 
HPLC 0.1 
µg/ml 
0.1 
µg/ml 
Non- 
compart-
mental 
model 
ND (30 
mg), 0.98 
(100 mg), 
1.87 (200  
mg), 2.6 
(300 mg) 
ND (30 
mg), 1.21 
± 0.1 (100 
mg), 1.3 
± 0.23 
(200  
mg), 1.4 
± 0.23 
(300 mg) 
ND (30 mg), 
1.42 (100 
mg), 1.28 
(200  mg), 
1.62 (300 
mg) 
0.19 (30 
mg), 0.16 
(100 mg), 
0.12 (200 
mg), 0.19 
(300 mg) 
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APPENDIX II 
 
 
COMPARISON OF PHYSICOCHEMICAL PROPERTIES OF FLUOROQUINOLONES 
ACROSS THE GROUPS SHOWING NET TUBULAR SECRETION (GROUP 3), 
REABSORPTION (GROUP 1) AND NO NET TRANSPORT (GROUP 2) 
 
 
 
 
FQs discussed in Chapter 3 were distributed into three Groups based on ‘net’ renal 
tubular clearance (CLren,tub): 
1. Group 1 FQs: Pefloxacin, Rufloxacin, Sparfloxacin  
(Net tubular reabsorption, CLren,tub < -1 ) 
2. Group 2 FQs: Antofloxacin*(excluded in the analysis as physicochemical properties could 
not be obtained by the ACD software), Fleroxacin, Grepafloxacin, Levofloxacin, 
Lomefloxacin, Moxifloxacin, Temafloxacin, Trovafloxacin  
(Little/No net transport, -1 < CLren,tub < 1 ) 
3. Group 3 FQs: Amifloxacin, Ciprofloxacin, Enoxacin, Gatifloxacin, Gemifloxacin, 
Norfloxacin, Ofloxacin  
(Net tubular secretion, CLren,tub > 1 ) 
 
 
 
  
147 
 
Molecular Properties compared among the Groups of FQs: Molecular weight, Log D 
(Logarithmic distribution coefficient) at pH 7.4, hydrogen bond donor (HBD), hydrogen bond 
acceptor (HBA), number of rotatable bonds (nRot), molar volume. Software: ACD Labs 
PhysChem Suite, Version 12. Statistical Analysis was conducted using JMP statistical software, 
Version 9.0.2. 
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1. Molecular Weight (MW):  
 
 
 
 
One-way ANOVA: 
 
Summary of Fit: 
 
Rsquare 0.053 
Adj Rsquare -0.082 
Root Mean Square Error 34.139 
Mean of Response 361.608 
Observations (FQs) 17 
 
Analysis of Variance: 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Group 2 914.86 457.43 0.39 0.6826 
Error 14 16316.15 1165.44   
C. Total 16 17231.01    
ANOVA indicates no significant difference among Group 1, 2 and 3 for MW. 
Summary Statistics for MW of the 3 Groups: 
Group Number Mean Std Error Lower 95% Upper 95% 
1 3 362.9 19.71 320.7 405.2 
2 8 368.3 12.07 342.4 394.2 
3 6 352.0 13.94 322.1 381.9 
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2. Log D at pH 7.4: 
 
One-way ANOVA: 
Summary of Fit: 
Rsquare 0.167 
Adj Rsquare 0.0480 
Root Mean Square Error 0.495 
Mean of Response -0.282 
Observations (FQs) 17 
 
Analysis of Variance:  
 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Group 2 0.69 0.34 1.40 0.2782 
Error 14 3.43 0.25   
C. Total 16 4.12    
ANOVA indicates no significant difference among Group 1, 2 and 3 for Log D at pH 7.4. 
Summary Statistics for LogD of the 3 Groups: 
Group Number Mean Std Error Lower 95% Upper 95% 
1 3 0.1 0.29 -0.5 0.7 
2 8 -0.3 0.18 -0.7 0.1 
3 6 -0.5 0.20 -0.9 -0.04 
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3. Hydrogen Bond Donor (HBD): 
 
 
 
One-way ANOVA: 
Summary of Fit: 
Rsquare 0.0061 
Adj Rsquare -0.135 
Root Mean Square Error 0.881 
Mean of Response 1.941 
Observations (or Sum Wgts) 17 
 
Analysis of Variance:  
 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Group 2 0.07 0.033 0.043 0.9584 
Error 14 10.88 0.78   
C. Total 16 10.94    
ANOVA indicates no significant difference among Group 1, 2 and 3 for HBD. 
Summary Statistics for HBD of the 3 Groups: 
Group Number Mean Std Error Lower 95% Upper 95% 
1 3 2.0 0.51 0.9 3.1 
2 8 1.9 0.31 1.2 2.5 
3 6 2.0 0.36 1.2 2.8 
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4. Hyrdogen Bond Acceptors (HBA): 
 
 
One-way ANOVA: 
Summary of Fit: 
Rsquare 0.254 
Adj Rsquare 0.147 
Root Mean Square Error 0.726 
Mean of Response 6.647 
Observations (FQs) 17 
 
Analysis of Variance:  
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Group 2 2.507 1.254 2.380 0.1289 
Error 14 7.375 0.527   
C. Total 16 9.882    
ANOVA indicates no significant difference among Group 1, 2 and 3 for HBA. 
Summary Statistics for HBD of the 3 Groups: 
Group Number Mean Std Error Lower 95% Upper 95% 
1 3 6.3 0.42 5.4 7.2 
2 8 6.4 0.26 5.8 6.9 
3 6 7.2 0.30 6.5 7.8 
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5. Number of Rotatable Bonds (nRot): 
 
One-way ANOVA: 
Summary of Fit: 
Rsquare 0.034 
Adj Rsquare -0.104 
Root Mean Square Error 1.035 
Mean of Response 3.294 
Observations (or Sum Wgts) 17 
 
Analysis of Variance:  
 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Group 2 0.529 0.265 0.247 0.7844 
Error 14 15.000 1.071   
C. Total 16 15.529    
ANOVA indicates no significant difference among Group 1, 2 and 3 for nRot. 
Summary Statistics for nRot of the 3 Groups: 
Group Number Mean Std Error Lower 95% Upper 95% 
1 3 3.0 0.60 1.7 4.3 
2 8 3.3 0.36 2.5 4.0 
3 6 3.5 0.42 2.6 4.4 
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6. Molar Volume: 
 
 
One-way ANOVA: 
Summary of Fit: 
Rsquare 0.290 
Adj Rsquare 0.188 
Root Mean Square Error 17.795 
Mean of Response 253.218 
Observations (FQs) 17 
 
Analysis of Variance: 
 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Group 2 1807.402 903.701 2.854 0.0913 
Error 14 4433.398 316.671   
C. Total 16 6240.801    
ANOVA indicates no significant difference among Group 1, 2 and 3 for Molar Volume. 
Summary Statistics for Molar Volume of the 3 Groups: 
Group Number Mean Std Error Lower 95% Upper 95% 
1 3 253.543 10.274 231.51 275.58 
2 8 262.988 6.292 249.49 276.48 
3 6 240.030 7.265 224.45 255.61 
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APPENDIX III 
 
 
INTERACTIONS OF THE FLUOROQUINOLONES IN THE PRELMINARY 
INTERACTION EXPERIMENTS WITH THE SOLUTE CARRIER 22 
TRANSPORTERS: INHIBITION, STIMULATION, OR NO INTERACTION 
 
 
 
 
 
Inhibition          ; Stimulation               ; No Interaction  00   
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No consistent pattern of interaction was observed for any particular FQ, when tested with: 
hOCT1, hOCT2, hOCT3, mOat1, hOAT1, mOat3, hOAT3, hOAT4 (treatment at pH 7.4 and 
6.3). Individual interactions are represented in the Figure above. 
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APPENDIX IV 
 
 
ASSESSMENT OF THE CLINICAL RELEVANCE OF MOUSE ORGANIC ANION 
TRANPORTER 3 IN THE RENAL ELIMINATION OF FLUOROQUINOLONES 
 
 
 
 
Inhibition constant (Ki values) were obtained for mOat3 with a selected subset of FQs (discussed 
in Chapter 5 and (187)). The following FQs were studied further to examine whether mOat3 
could potentially be a rate-limiting step in their in vivo elimination, suggesting possible species 
difference in renal handling of FQs (as human OAT3 did not demonstrate significant in vitro 
interactions with FQs in preliminary studies). 
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Pharmacokinetic preclinical studies of FQs conducted in mice: 
1. ENOXACIN: 
 
 
FQ: 
Study 
Species, 
BW 
Dose 
and 
Route 
(mg) 
Sampling 
Schedule 
Assay LOQ PK 
Analysis 
PK Endpoints Ki in 
mOat3 
(µM) 
Plasma Urine Plasma 
and/or 
Urine 
AUC 
(mg*min/
ml) 
CLtot 
(ml/min/
kg) 
CLren 
(ml/min/kg) 
fu 
(%) 
CLren
u 
(ml/min/
kg)
 
Shinic
hi N et. 
al. 
(117) 
Std-
DDY 
mice, 
n=40 
(plasma 
tests), 9 
(urine 
tests), 
26-32 g 
50 
mg/kg 
(1.45 
mg, 
chose
n on 
avera
ge) 
0-8 hrs 0-24  
hrs 
Bioassay: 
thin layer 
cup-
method 
with 
E.coli; 
Protein 
binding 
study by 
rapid 
ultrafiltra
tion 
0.04 
µg/ml 
One- 
compart-
mental 
model 
0.45 - 65.6 72.
4 
90.6 396 ± 
15 
(Chapt
er 5) 
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2. NORFLOXACIN:  
 
 
FQ: Study Species
, BW 
Dose 
and 
Route 
(mg) 
Sampling 
Schedule 
Assay LOQ PK 
Analysis 
PK Endpoints Ki in 
mOat3 
(µM) 
Plasma Urine Plasma 
and/or 
Urine 
AUC 
(mg*min
/ml) 
CLtot 
(ml/min/
kg) 
CLren 
(ml/min/
kg) 
fu 
(%) 
CLren
u 
(ml/min/
kg)
 
Norfloxaci
n: Shinichi 
N et. al. 
(117) 
Std-
DDY 
mice, 
n=40 
(plasma 
tests), 9 
(urine 
tests), 
26-32 g 
50 
mg/kg 
(1.45 
mg, 
chose
n on 
averag
e) 
0-4 hrs 0-24  
hrs 
Bioassay: 
thin layer 
cup-
method 
with 
E.coli; 
Protein 
binding 
study by 
rapid 
ultrafiltra
tion 
0.04 
µg/ml 
One- 
compartme
ntal model 
0.065 - 34.8 60.2 57.8 558 ± 75 
(187) 
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3. MOXIFLOXACIN: 
 
FQ: 
Study 
Species, 
BW 
Dose 
and 
Route 
(mg) 
Sampling 
Schedule 
Assay LOQ PK 
Analysis 
PK Endpoints Ki in 
mOat3 
(µM) 
Plasma Urine Plasma 
and/or 
Urine 
AUC 
(mg*min/
ml) 
CLtot 
(ml/min/kg) 
CLren 
(ml/min/
kg) 
fu 
(%) 
CLren
u 
(ml/min/
kg)
 
Siefert 
HM et. 
al. (145) 
Male 
NMRI 
mice, 
n= 3 per 
time 
point, 
26-43 g, 
6 weeks 
old 
9.2 
mg/kg, 
IV 
dose 
0-4 hrs - HPLC, 
Urine 
(and 
plasma) 
were 
assay-
ed by 
scintill-
ation 
count-
ing; 
Protein 
binding 
assay by 
ultrafiltr
ation 
5.0 
µg/ml 
for 
plasma 
Non- 
compart-
mental 
0.13 70.2 10.3 69 14.9 1356 ± 
114 
(Chapter 
5) 
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4. SPARFLOXACIN: 
 
FQ: 
Study 
Species, 
BW 
Dose 
and 
Route 
(mg) 
Sampling 
Schedule 
Assay LOQ PK 
Analysis 
PK Endpoints Ki in 
mOat3 
(µM) 
Plasma Urine Plasma 
and/or 
Urine 
AUC 
(mg*min
/ml) 
CLtot 
(ml/min/kg
) 
CLren 
(ml/min/kg) 
fu 
(%) 
CLren
u 
(ml/min/
kg)
 
Siefert 
HM et. 
al. (145) 
Male 
Std-ddY 
mice, 
n= 5 per 
time 
point, 
22-38 g, 
6 weeks 
old 
5 
mg/kg, 
IV 
dose 
0.25 - 8 
hrs 
0-48 
hrs 
poole
d for 
group 
of 5 
mice 
Agar 
well 
diffu-
sion 
metho
d with 
E. coli 
Kp; 
Protein 
bind-
ing 
consid
ered 
from a 
prev-
ious 
analy-
sis 
0.01 
µg/ml 
One or 
two- 
compart-
ment 
open 
model 
0.044 - 7.6 56 13.5 205 ± 12 
 
(Chapter 5) 
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From these mice preclinical studies, and the Ki values determined from an earlier study in 
Chapter 5, it was further studied if the increase/decrease in Ki values (i.e., binding affinity) of FQ 
inhibitors for mOat3 could potentially affect their CLren
u
 (further affecting CLren,tub in mice). 
Statistical Analysis was conducted using JMP statistical software, Version 9.0.2. 
 
FQ ~Ki values for mOat3 
(µM) 
CLren
u  
from the studies in 
mice (ml/min/kg) 
Enoxacin 396 90.6 
Norfloxacin 558 57.8 
Moxifloxacin 1356 14.9 
Sparfloxacin 205 13.5 
 
 
 
Linear Fit Equation: CLren
u
 mouse = 63.168 - 0.0321*Ki mOat3 (UM) 
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Summary of Fit:  
RSquare 0.215 
RSquare Adj -0.178 
Root Mean Square Error 40.267 
Mean of Response 44.275 
Observations (FQs) 4 
 
Analysis of Variance 
 
Source DF Sum of 
Squares 
Mean Square F Ratio 
Model 1 886.49 886.49 0.5467 
Error 2 3242.88 1621.44 Prob > F 
C. Total 3 4129.37  0.5367 
 
When this univariate relationship was assessed by the linear regression analysis, it demonstrated 
that there was no significant linear relationship between the CLren
u 
in mice and the Ki values of 
the FQs for mOat3. This demonstrated that mOat3 may not be the rate-limiting transporter for 
the overall renal clearance of these FQs. However, a larger dataset of FQ preclinical (mice) 
studies and mOat3 Ki values would be essential to build stronger conclusions. 
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